Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
23,200 | 2022-08-03 00:00:00 UTC | Is Invesco Dynamic Pharmaceuticals ETF (PJP) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-invesco-dynamic-pharmaceuticals-etf-pjp-a-strong-etf-right-now-3 | null | null | The Invesco Dynamic Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the marke... | When you look at individual holdings, Eli Lilly & Co (LLY) accounts for about 5.80% of the fund's total assets, followed by Abbvie Inc (ABBV) and Johnson & Johnson (JNJ). AbbVie Inc. (ABBV): Free Stock Analysis Report However, some investors believe in the possibility of beating the market through exceptional stock sel... | When you look at individual holdings, Eli Lilly & Co (LLY) accounts for about 5.80% of the fund's total assets, followed by Abbvie Inc (ABBV) and Johnson & Johnson (JNJ). AbbVie Inc. (ABBV): Free Stock Analysis Report Invesco Dynamic Pharmaceuticals ETF (PJP): ETF Research Reports | When you look at individual holdings, Eli Lilly & Co (LLY) accounts for about 5.80% of the fund's total assets, followed by Abbvie Inc (ABBV) and Johnson & Johnson (JNJ). AbbVie Inc. (ABBV): Free Stock Analysis Report The Invesco Dynamic Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange... | When you look at individual holdings, Eli Lilly & Co (LLY) accounts for about 5.80% of the fund's total assets, followed by Abbvie Inc (ABBV) and Johnson & Johnson (JNJ). AbbVie Inc. (ABBV): Free Stock Analysis Report The Invesco Dynamic Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange... |
23,201 | 2022-08-03 00:00:00 UTC | Medicare Drug Pricing Changes Could Be Coming: Time to Ditch Pharma Stocks? | ABBV | https://www.nasdaq.com/articles/medicare-drug-pricing-changes-could-be-coming%3A-time-to-ditch-pharma-stocks | null | null | Two types of stocks have performed well overall so far this year as the broader market has tanked. It makes sense that energy stocks would be up, considering the high prices of oil and natural gas. Several big pharmaceutical companies have also beaten the market in 2022 as investors viewed them as safe havens.
However,... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) together market the costliest drug for Medicare Part D in 2020 -- cancer treatment Imbruvica. Unsurprisingly, AbbVie CEO Rick Gonzalez said on his company's Q2 call that the proposed bill "has far more negatives than it has positives in it." See the 10 stocks *Stock... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) together market the costliest drug for Medicare Part D in 2020 -- cancer treatment Imbruvica. Unsurprisingly, AbbVie CEO Rick Gonzalez said on his company's Q2 call that the proposed bill "has far more negatives than it has positives in it." See the 10 stocks *Stock... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) together market the costliest drug for Medicare Part D in 2020 -- cancer treatment Imbruvica. Unsurprisingly, AbbVie CEO Rick Gonzalez said on his company's Q2 call that the proposed bill "has far more negatives than it has positives in it." See the 10 stocks *Stock... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) together market the costliest drug for Medicare Part D in 2020 -- cancer treatment Imbruvica. Unsurprisingly, AbbVie CEO Rick Gonzalez said on his company's Q2 call that the proposed bill "has far more negatives than it has positives in it." See the 10 stocks *Stock... |
23,202 | 2022-08-03 00:00:00 UTC | 1 Reason to Buy Pfizer Stock After Earnings, and 1 Reason to Sell | ABBV | https://www.nasdaq.com/articles/1-reason-to-buy-pfizer-stock-after-earnings-and-1-reason-to-sell | null | null | The year hasn't been kind to equities so far. And although many drugmakers are escaping the sell-off, Pfizer (NYSE: PFE) isn't one of them. The pharma giant is performing more or less on par with the broader market year to date. Thankfully, Pfizer's most recent quarterly update showed some very encouraging signs.
Howev... | Last year, Pfizer released data from a post-marketing study that found that Xeljanz was associated with higher rates of cardiovascular events and cancer than TNF inhibitors, a category of medicines that includes AbbVie's Humira. PFE data by YCharts Reason to buy: The COVID-19 portfolio is performing well Pfizer has mad... | Last year, Pfizer released data from a post-marketing study that found that Xeljanz was associated with higher rates of cardiovascular events and cancer than TNF inhibitors, a category of medicines that includes AbbVie's Humira. PFE data by YCharts Reason to buy: The COVID-19 portfolio is performing well Pfizer has mad... | Last year, Pfizer released data from a post-marketing study that found that Xeljanz was associated with higher rates of cardiovascular events and cancer than TNF inhibitors, a category of medicines that includes AbbVie's Humira. PFE data by YCharts Reason to buy: The COVID-19 portfolio is performing well Pfizer has mad... | Last year, Pfizer released data from a post-marketing study that found that Xeljanz was associated with higher rates of cardiovascular events and cancer than TNF inhibitors, a category of medicines that includes AbbVie's Humira. In the second quarter, Xeljanz's sales dropped by 24% year over year to $430 million. Durin... |
23,203 | 2022-08-03 00:00:00 UTC | Allegan Aesthetics Of AbbVie Gets FDA Approval For Juvederm Volux XC For Jawline Treatment | ABBV | https://www.nasdaq.com/articles/allegan-aesthetics-of-abbvie-gets-fda-approval-for-juvederm-volux-xc-for-jawline-treatment | null | null | (RTTNews) - AbbVie Co.'s (ABBV) Allergan Aesthetics Wednesday announced FDA approval for its Juvederm Volux XC for improvement of jawline in adults, with moderate to a severe loss of jawline definition.
Juvederm helps in cohesivity and lift capacity to create an improved jawline that appears more defined in real life.
... | (RTTNews) - AbbVie Co.'s (ABBV) Allergan Aesthetics Wednesday announced FDA approval for its Juvederm Volux XC for improvement of jawline in adults, with moderate to a severe loss of jawline definition. Juvederm helps in cohesivity and lift capacity to create an improved jawline that appears more defined in real life. ... | (RTTNews) - AbbVie Co.'s (ABBV) Allergan Aesthetics Wednesday announced FDA approval for its Juvederm Volux XC for improvement of jawline in adults, with moderate to a severe loss of jawline definition. Juvederm helps in cohesivity and lift capacity to create an improved jawline that appears more defined in real life. ... | (RTTNews) - AbbVie Co.'s (ABBV) Allergan Aesthetics Wednesday announced FDA approval for its Juvederm Volux XC for improvement of jawline in adults, with moderate to a severe loss of jawline definition. The company noted that in the pivotal clinical study Juvederm was found to effectively improve jawline definition at ... | (RTTNews) - AbbVie Co.'s (ABBV) Allergan Aesthetics Wednesday announced FDA approval for its Juvederm Volux XC for improvement of jawline in adults, with moderate to a severe loss of jawline definition. Juvederm helps in cohesivity and lift capacity to create an improved jawline that appears more defined in real life. ... |
23,204 | 2022-08-02 00:00:00 UTC | Analysts Anticipate 15% Gains Ahead For MGV | ABBV | https://www.nasdaq.com/articles/analysts-anticipate-15-gains-ahead-for-mgv | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Mega Cap Value ETF (Sy... | Vanguard Mega Cap Value ETF MGV $100.29 $114.96 14.63% Wells Fargo & Co WFC $43.54 $54.46 25.09% AbbVie Inc ABBV $140.22 $165.20 17.81% Abbott Laboratories ABT $109.52 $127.15 16.10% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of MGV's... | Three of MGV's underlying holdings with notable upside to their analyst target prices are Wells Fargo & Co (Symbol: WFC), AbbVie Inc (Symbol: ABBV), and Abbott Laboratories (Symbol: ABT). Similarly, ABBV has 17.81% upside from the recent share price of $140.22 if the average analyst target price of $165.20/share is rea... | Similarly, ABBV has 17.81% upside from the recent share price of $140.22 if the average analyst target price of $165.20/share is reached, and analysts on average are expecting ABT to reach a target price of $127.15/share, which is 16.10% above the recent price of $109.52. Three of MGV's underlying holdings with notable... | Vanguard Mega Cap Value ETF MGV $100.29 $114.96 14.63% Wells Fargo & Co WFC $43.54 $54.46 25.09% AbbVie Inc ABBV $140.22 $165.20 17.81% Abbott Laboratories ABT $109.52 $127.15 16.10% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of MGV's... |
23,205 | 2022-08-02 00:00:00 UTC | These Blue-Chip Stocks Seem Attractive at Current Levels | ABBV | https://www.nasdaq.com/articles/these-blue-chip-stocks-seem-attractive-at-current-levels | null | null | Despite the strong recovery in the U.S. stock market in July, investors remain wary of sky-high inflation and macro uncertainty. During these challenging times, several investors consider blue-chip stocks to be safer bets. Blue-chip stocks are stocks of large, well-established companies that have a solid track record, ... | Piper Sandler analyst Christopher Raymond noted that AbbVie missed revenue expectations for the second straight quarter, which doesn’t look good as the company is generally considered a safe haven stock both within the sector and in a recessionary backdrop. Using the TipRanks Stock Comparison Tool, we placed AbbVie, 3M... | Using the TipRanks Stock Comparison Tool, we placed AbbVie, 3M, and Microsoft against each other to pick the blue-chip stock that Wall Street analysts find more favorable at current levels. AbbVie (NYSE: ABBV) Biopharma company AbbVie recently reported better-than-anticipated adjusted earnings of $3.37 per share (up 11... | Using the TipRanks Stock Comparison Tool, we placed AbbVie, 3M, and Microsoft against each other to pick the blue-chip stock that Wall Street analysts find more favorable at current levels. Piper Sandler analyst Christopher Raymond noted that AbbVie missed revenue expectations for the second straight quarter, which doe... | Using the TipRanks Stock Comparison Tool, we placed AbbVie, 3M, and Microsoft against each other to pick the blue-chip stock that Wall Street analysts find more favorable at current levels. AbbVie (NYSE: ABBV) Biopharma company AbbVie recently reported better-than-anticipated adjusted earnings of $3.37 per share (up 11... |
23,206 | 2022-07-31 00:00:00 UTC | If You Invested $25,000 in Abbott Laboratories in 2013, This Is How Much You Would Have Today | ABBV | https://www.nasdaq.com/articles/if-you-invested-%2425000-in-abbott-laboratories-in-2013-this-is-how-much-you-would-have | null | null | It has been more than nine years since Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV). By doing so, AbbVie could focus on research and developing breakthrough therapies while Abbott could remain a diversified healthcare company focused on generic pharmaceuticals, medical devices, diagnostics, and nutritio... | Investors would have made out well on the investment, but they would have enjoyed even better gains from holding shares of the growth-oriented AbbVie instead; its value has risen by more than 330% since inception, while Abbott's stock price has climbed by 239%. It has been more than nine years since Abbott Laboratories... | By doing so, AbbVie could focus on research and developing breakthrough therapies while Abbott could remain a diversified healthcare company focused on generic pharmaceuticals, medical devices, diagnostics, and nutrition. It has been more than nine years since Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV... | By doing so, AbbVie could focus on research and developing breakthrough therapies while Abbott could remain a diversified healthcare company focused on generic pharmaceuticals, medical devices, diagnostics, and nutrition. Investors would have made out well on the investment, but they would have enjoyed even better gain... | It has been more than nine years since Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV). By doing so, AbbVie could focus on research and developing breakthrough therapies while Abbott could remain a diversified healthcare company focused on generic pharmaceuticals, medical devices, diagnostics, and nutritio... |
23,207 | 2022-07-31 00:00:00 UTC | 3 Dividend Aristocrats to Buy in August | ABBV | https://www.nasdaq.com/articles/3-dividend-aristocrats-to-buy-in-august | null | null | Track records matter. And when it comes to dividends, there's a group of stocks that have especially impressive track records. These stocks don't just reliably pay dividends; they've consistently increased their dividends for 25 or more years in a row.
I'm referring, of course, to Dividend Aristocrats. Not every member... | The main knock against AbbVie is that autoimmune-disease drug Humira faces biosimilar competition in the U.S. beginning next year. AbbVie AbbVie (NYSE: ABBV) has increased its dividend for 50 consecutive years. AbbVie has grown its dividend payout by more than 250% since 2013 with the dividend yield now topping 3.7%. | AbbVie AbbVie (NYSE: ABBV) has increased its dividend for 50 consecutive years. Abbot Laboratories Abbott Laboratories (NYSE: ABT) boasts a 50-year history of annual dividend hikes like AbbVie does. AbbVie has grown its dividend payout by more than 250% since 2013 with the dividend yield now topping 3.7%. | AbbVie AbbVie (NYSE: ABBV) has increased its dividend for 50 consecutive years. PepsiCo PepsiCo (NASDAQ: PEP) belongs to the same club as AbbVie and Abbott, increasing its dividend for 50 consecutive years. AbbVie has grown its dividend payout by more than 250% since 2013 with the dividend yield now topping 3.7%. | AbbVie AbbVie (NYSE: ABBV) has increased its dividend for 50 consecutive years. AbbVie has grown its dividend payout by more than 250% since 2013 with the dividend yield now topping 3.7%. AbbVie's share price has soared more than 120% over the past three years. |
23,208 | 2022-07-30 00:00:00 UTC | Earn $300 in Quarterly Retirement Dividends With 3 Easy Steps | ABBV | https://www.nasdaq.com/articles/earn-%24300-in-quarterly-retirement-dividends-with-3-easy-steps | null | null | Generating passive income through dividends is particularly important these days, as the stock market has had negative returns for the better part of a year now. But it is perhaps even more important in retirement, as that added income can come in handy. It can certainly give you some spending money to supplement your ... | Another is pharmaceutical company AbbVie (NYSE: ABBV), which has a yield of 3.75% and a quarterly dividend payout of $1.41, with a payout ratio of 42%. AbbVie has increased its dividend for 50 straight years. It is also worth noting that AbbVie is up 12% year to date (YTD) and has posted an average annual return of 16%... | T. Rowe Price has posted an annualized return of 7% over the past 10 years, while AbbVie has posted a 16% average annual return. Another is pharmaceutical company AbbVie (NYSE: ABBV), which has a yield of 3.75% and a quarterly dividend payout of $1.41, with a payout ratio of 42%. AbbVie has increased its dividend for 5... | Another is pharmaceutical company AbbVie (NYSE: ABBV), which has a yield of 3.75% and a quarterly dividend payout of $1.41, with a payout ratio of 42%. AbbVie has increased its dividend for 50 straight years. It is also worth noting that AbbVie is up 12% year to date (YTD) and has posted an average annual return of 16%... | Another is pharmaceutical company AbbVie (NYSE: ABBV), which has a yield of 3.75% and a quarterly dividend payout of $1.41, with a payout ratio of 42%. AbbVie has increased its dividend for 50 straight years. It is also worth noting that AbbVie is up 12% year to date (YTD) and has posted an average annual return of 16%... |
23,209 | 2022-07-30 00:00:00 UTC | 3 Stocks We Think Could Beat the Market in the Second Half of 2022 | ABBV | https://www.nasdaq.com/articles/3-stocks-we-think-could-beat-the-market-in-the-second-half-of-2022 | null | null | Every investor wants alpha -- the extra return above what a benchmark index generates. Many stocks don't deliver alpha at all, but some do.
We asked three Motley Fool contributors to identify stocks they think could beat the market in the second half of the year. Here's why they chose AbbVie (NYSE: ABBV), AstraZeneca (... | While it will lose patent exclusivity for its blockbuster rheumatoid arthritis medicine Humira next year, sales for AbbVie's newer immunology products -- Skyrizi and Rinvoq -- continue to grow rapidly. But thanks to its solid lineup, juicy dividend, and reasonable valuation, AbbVie can help investors through these diff... | Here's why they chose AbbVie (NYSE: ABBV), AstraZeneca (NASDAQ: AZN), and Johnson & Johnson (NYSE: JNJ). Ride out the bear market with this big drugmaker Prosper Junior Bakiny (AbbVie): The year has been good for pharma giant AbbVie, at least so far. AbbVie benefits from the fact that lifesaving medicines are in high d... | As safe as they come Keith Speights (Johnson & Johnson): I think that Johnson & Johnson is likely to outperform the market during the second half of 2022 for several of the same reasons that my colleagues gave for AbbVie and AstraZeneca. Here's why they chose AbbVie (NYSE: ABBV), AstraZeneca (NASDAQ: AZN), and Johnson ... | Here's why they chose AbbVie (NYSE: ABBV), AstraZeneca (NASDAQ: AZN), and Johnson & Johnson (NYSE: JNJ). Ride out the bear market with this big drugmaker Prosper Junior Bakiny (AbbVie): The year has been good for pharma giant AbbVie, at least so far. AbbVie benefits from the fact that lifesaving medicines are in high d... |
23,210 | 2022-07-29 00:00:00 UTC | AbbVie: RINVOQ Approved In EU To Treat Adults With Active Non-Radiographic Axial Spondyloarthritis | ABBV | https://www.nasdaq.com/articles/abbvie%3A-rinvoq-approved-in-eu-to-treat-adults-with-active-non-radiographic-axial | null | null | (RTTNews) - AbbVie (ABBV) announced Friday that the European Commission has approved RINVOQ (upadacitinib 15 mg, once daily) as an oral treatment for adults with Active Non-Radiographic Axial Spondyloarthritis or axSpA.
axSpA is a chronic, progressive and disabling inflammatory rheumatic disease that causes joint infla... | (RTTNews) - AbbVie (ABBV) announced Friday that the European Commission has approved RINVOQ (upadacitinib 15 mg, once daily) as an oral treatment for adults with Active Non-Radiographic Axial Spondyloarthritis or axSpA. AbbVie previously disclosed topline results from the Phase 3 SELECT-AXIS 2 nr-axSpA clinical trial a... | (RTTNews) - AbbVie (ABBV) announced Friday that the European Commission has approved RINVOQ (upadacitinib 15 mg, once daily) as an oral treatment for adults with Active Non-Radiographic Axial Spondyloarthritis or axSpA. AbbVie previously disclosed topline results from the Phase 3 SELECT-AXIS 2 nr-axSpA clinical trial a... | (RTTNews) - AbbVie (ABBV) announced Friday that the European Commission has approved RINVOQ (upadacitinib 15 mg, once daily) as an oral treatment for adults with Active Non-Radiographic Axial Spondyloarthritis or axSpA. AbbVie previously disclosed topline results from the Phase 3 SELECT-AXIS 2 nr-axSpA clinical trial a... | (RTTNews) - AbbVie (ABBV) announced Friday that the European Commission has approved RINVOQ (upadacitinib 15 mg, once daily) as an oral treatment for adults with Active Non-Radiographic Axial Spondyloarthritis or axSpA. AbbVie previously disclosed topline results from the Phase 3 SELECT-AXIS 2 nr-axSpA clinical trial a... |
23,211 | 2022-07-29 00:00:00 UTC | ABBV Crosses Below Key Moving Average Level | ABBV | https://www.nasdaq.com/articles/abbv-crosses-below-key-moving-average-level | null | null | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $140.72, changing hands as low as $139.82 per share. AbbVie Inc shares are currently trading down about 6.4% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving averag... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $140.72, changing hands as low as $139.82 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $140.72, changing hands as low as $139.82 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $140.72, changing hands as low as $139.82 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range... | In trading on Friday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $140.72, changing hands as low as $139.82 per share. AbbVie Inc shares are currently trading down about 6.4% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving averag... |
23,212 | 2022-07-29 00:00:00 UTC | AbbVie (ABBV) Q2 2022 Earnings Call Transcript | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q2-2022-earnings-call-transcript | null | null | Image source: The Motley Fool.
AbbVie (NYSE: ABBV)
Q2 2022 Earnings Call
Jul 29, 2022, 9:00 a.m. ET
Contents:
Prepared Remarks
Questions and Answers
Call Participants
Prepared Remarks:
Operator
Good morning and thank you for standing by. Welcome to the AbbVie second quarter 2022earnings conference call [Operator instr... | AbbVie (NYSE: ABBV) Q2 2022 Earnings Call Jul 29, 2022, 9:00 a.m. Welcome to the AbbVie second quarter 2022earnings conference call [Operator instructions] I would now like to introduce Ms. Liz Shea, vice president, head of investor relations. AbbVie cautions that these forward-looking statements are subject to risks a... | Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Tom Hudson -- Senior Vice President, Research and Development and Chief Sci... | Operator [Operator signoff] Duration: 0 minutes Call participants: Liz Shea -- Vice President, Investor Relations Rick Gonzalez -- Chairman of the Board and Chief Executive Officer Jeff Stewart -- Executive Vice President, Commercial Operations Tom Hudson -- Senior Vice President, Research and Development and Chief Sci... | AbbVie (NYSE: ABBV) Q2 2022 Earnings Call Jul 29, 2022, 9:00 a.m. Welcome to the AbbVie second quarter 2022earnings conference call [Operator instructions] I would now like to introduce Ms. Liz Shea, vice president, head of investor relations. AbbVie cautions that these forward-looking statements are subject to risks a... |
23,213 | 2022-07-29 00:00:00 UTC | AbbVie (ABBV) Q2 Earnings Beat Estimates | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q2-earnings-beat-estimates | null | null | AbbVie (ABBV) came out with quarterly earnings of $3.37 per share, beating the Zacks Consensus Estimate of $3.31 per share. This compares to earnings of $3.11 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 1.81%. A quarter ago, it was e... | AbbVie (ABBV) came out with quarterly earnings of $3.37 per share, beating the Zacks Consensus Estimate of $3.31 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.58 billion for the quarter ended June 2022, missing the Zacks Consensus Estimate by 0.48%. AbbVie shar... | AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.58 billion for the quarter ended June 2022, missing the Zacks Consensus Estimate by 0.48%. AbbVie (ABBV) came out with quarterly earnings of $3.37 per share, beating the Zacks Consensus Estimate of $3.31 per share. AbbVie shar... | AbbVie (ABBV) came out with quarterly earnings of $3.37 per share, beating the Zacks Consensus Estimate of $3.31 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.58 billion for the quarter ended June 2022, missing the Zacks Consensus Estimate by 0.48%. AbbVie shar... | AbbVie (ABBV) came out with quarterly earnings of $3.37 per share, beating the Zacks Consensus Estimate of $3.31 per share. AbbVie, which belongs to the Zacks Large Cap Pharmaceuticals industry, posted revenues of $14.58 billion for the quarter ended June 2022, missing the Zacks Consensus Estimate by 0.48%. AbbVie shar... |
23,214 | 2022-07-29 00:00:00 UTC | Why AbbVie Stock Is Tanking Today | ABBV | https://www.nasdaq.com/articles/why-abbvie-stock-is-tanking-today | null | null | What happened
Shares of the Illinois-based drugmaker AbbVie (NYSE: ABBV) were down by a hefty 5% as of 2:32 p.m. ET Friday afternoon. As a result, the Dividend Aristocrat's market capitalization has slipped by a staggering $13.2 billion today.
Why are investors hitting the exits today? Ahead of the opening bell, AbbVie... | So what Specifically, AbbVie's aesthetics portfolio posted a 4.4% dip in year-over-year sales in Q2 due to the impact of COVID-19 restrictions in China, as well as the suspension of operations in Russia. AbbVie's normally strong cancer unit contracted in the most recent quarter mainly due to a 17.1% drop in net revenue... | So what Specifically, AbbVie's aesthetics portfolio posted a 4.4% dip in year-over-year sales in Q2 due to the impact of COVID-19 restrictions in China, as well as the suspension of operations in Russia. What happened Shares of the Illinois-based drugmaker AbbVie (NYSE: ABBV) were down by a hefty 5% as of 2:32 p.m. Ahe... | Now what Is AbbVie's stock a buy on today's downturn? AbbVie's stock, for instance, was up by a handsome 10.6% for the year prior to today's dip. 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. | Now what Is AbbVie's stock a buy on today's downturn? * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! What happened Shares of the Illinois-based drugmaker AbbVie (NYSE: ABBV) were down by a hefty 5% as of 2:32 p.m. |
23,215 | 2022-07-29 00:00:00 UTC | AbbVie Confirms FY22 Adj. EPS Outlook - Update | ABBV | https://www.nasdaq.com/articles/abbvie-confirms-fy22-adj.-eps-outlook-update | null | null | (RTTNews) - While reporting financial results for the second quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) confirmed its adjusted earnings guidance for the full-year 2022.
For fiscal 2022, AbbVie continues to project adjusted earnings in a range of $13.78 to $13.98, which includes an unfavorable impac... | (RTTNews) - While reporting financial results for the second quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) confirmed its adjusted earnings guidance for the full-year 2022. For fiscal 2022, AbbVie continues to project adjusted earnings in a range of $13.78 to $13.98, which includes an unfavorable impac... | (RTTNews) - While reporting financial results for the second quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) confirmed its adjusted earnings guidance for the full-year 2022. For fiscal 2022, AbbVie continues to project adjusted earnings in a range of $13.78 to $13.98, which includes an unfavorable impac... | For fiscal 2022, AbbVie continues to project adjusted earnings in a range of $13.78 to $13.98, which includes an unfavorable impact of $0.23 per share related to acquired IPR&D and milestones expense incurred year-to-date through the second quarter 2022. (RTTNews) - While reporting financial results for the second quar... | (RTTNews) - While reporting financial results for the second quarter on Friday, biopharmaceutical company AbbVie Inc. (ABBV) confirmed its adjusted earnings guidance for the full-year 2022. For fiscal 2022, AbbVie continues to project adjusted earnings in a range of $13.78 to $13.98, which includes an unfavorable impac... |
23,216 | 2022-07-29 00:00:00 UTC | AbbVie sets aside $2 billion to settle U.S. opioid claims | ABBV | https://www.nasdaq.com/articles/abbvie-sets-aside-%242-billion-to-settle-u.s.-opioid-claims | null | null | Compares profit with estimates, adds share movement
July 29 (Reuters) - AbbVie Inc ABBV.N has set aside about $2 billion to resolve thousands of lawsuits against its Allergan unit over the marketing of its opioid products, the company said on Friday.
No final deal has been announced. AbbVie faces more than 3,000 lawsui... | Compares profit with estimates, adds share movement July 29 (Reuters) - AbbVie Inc ABBV.N has set aside about $2 billion to resolve thousands of lawsuits against its Allergan unit over the marketing of its opioid products, the company said on Friday. Despite the charge, AbbVie on Friday reported an adjusted profit of $... | Despite the charge, AbbVie on Friday reported an adjusted profit of $3.37 per share, beating the $3.31 expected by analysts, according to Refinitiv data. Compares profit with estimates, adds share movement July 29 (Reuters) - AbbVie Inc ABBV.N has set aside about $2 billion to resolve thousands of lawsuits against its ... | Compares profit with estimates, adds share movement July 29 (Reuters) - AbbVie Inc ABBV.N has set aside about $2 billion to resolve thousands of lawsuits against its Allergan unit over the marketing of its opioid products, the company said on Friday. AbbVie faces more than 3,000 lawsuits from state and local government... | Despite the charge, AbbVie on Friday reported an adjusted profit of $3.37 per share, beating the $3.31 expected by analysts, according to Refinitiv data. Compares profit with estimates, adds share movement July 29 (Reuters) - AbbVie Inc ABBV.N has set aside about $2 billion to resolve thousands of lawsuits against its ... |
23,217 | 2022-07-29 00:00:00 UTC | AbbVie Q2 22 Earnings Conference Call At 9:00 AM ET | ABBV | https://www.nasdaq.com/articles/abbvie-q2-22-earnings-conference-call-at-9%3A00-am-et | null | null | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 29, 2022, to discuss Q2 22 earnings results.
To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events
The views and opinions expressed herein are the views and opinions of the author and do not... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 29, 2022, to discuss Q2 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 29, 2022, to discuss Q2 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 29, 2022, to discuss Q2 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not... | (RTTNews) - AbbVie (ABBV) will host a conference call at 9:00 AM ET on July 29, 2022, to discuss Q2 22 earnings results. To access the live webcast, log on to https://investors.abbvie.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not... |
23,218 | 2022-07-29 00:00:00 UTC | Top Stock Market News For Today July 29, 2022 | ABBV | https://www.nasdaq.com/articles/top-stock-market-news-for-today-july-29-2022 | null | null | Stock Market Futures Gain Ahead Of Key Inflation Data
U.S. stock futures are trading higher early Friday morning. In general, this could be due to better-than-expected big tech earnings, and key GDP data released on Thursday. Investors will get earnings data from more notable names in the stock on Friday. Such as Chevr... | Such as Chevron (NYSE: CVX), AbbVie (NYSE: ABBV), Colgate-Palmolive (NYSE: CL), and many others. In general, this could be due to better-than-expected big tech earnings, and key GDP data released on Thursday. Additionally, the news adds fuel to a positively-received second quarter U.S. corporate earnings season. | Such as Chevron (NYSE: CVX), AbbVie (NYSE: ABBV), Colgate-Palmolive (NYSE: CL), and many others. Stock Market Futures Gain Ahead Of Key Inflation Data U.S. stock futures are trading higher early Friday morning. This comes as investors react positively to earnings results from Apple (NASDAQ: AAPL) and Amazon (NASDAQ: AM... | Such as Chevron (NYSE: CVX), AbbVie (NYSE: ABBV), Colgate-Palmolive (NYSE: CL), and many others. In the report, Amazon reported earnings per share of $0.10 on revenue of $121.2 billion. 4 In Focus Shares Of Apple (AMZN Stock) Rally After Reporting Stronger-Than-Expected Third Quarter Earnings Next, let’s check out cons... | Such as Chevron (NYSE: CVX), AbbVie (NYSE: ABBV), Colgate-Palmolive (NYSE: CL), and many others. This comes as investors react positively to earnings results from Apple (NASDAQ: AAPL) and Amazon (NASDAQ: AMZN). In the report, Amazon reported earnings per share of $0.10 on revenue of $121.2 billion. |
23,219 | 2022-07-29 00:00:00 UTC | AbbVie Q2 Profit Increases, beats estimates | ABBV | https://www.nasdaq.com/articles/abbvie-q2-profit-increases-beats-estimates | null | null | (RTTNews) - AbbVie (ABBV) reported a profit for its second quarter that increased from last year and beat the Street estimates.
The company's earnings came in at $924 million, or $0.51 per share. This compares with $766 million, or $0.42 per share, in last year's second quarter.
Excluding items, AbbVie reported adjuste... | (RTTNews) - AbbVie (ABBV) reported a profit for its second quarter that increased from last year and beat the Street estimates. Excluding items, AbbVie reported adjusted earnings of $3.37 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q2): $924 Mln. | Excluding items, AbbVie reported adjusted earnings of $3.37 per share for the period. (RTTNews) - AbbVie (ABBV) reported a profit for its second quarter that increased from last year and beat the Street estimates. AbbVie earnings at a glance (GAAP) : -Earnings (Q2): $924 Mln. | (RTTNews) - AbbVie (ABBV) reported a profit for its second quarter that increased from last year and beat the Street estimates. Excluding items, AbbVie reported adjusted earnings of $3.37 per share for the period. AbbVie earnings at a glance (GAAP) : -Earnings (Q2): $924 Mln. | Excluding items, AbbVie reported adjusted earnings of $3.37 per share for the period. (RTTNews) - AbbVie (ABBV) reported a profit for its second quarter that increased from last year and beat the Street estimates. AbbVie earnings at a glance (GAAP) : -Earnings (Q2): $924 Mln. |
23,220 | 2022-07-28 00:00:00 UTC | Noteworthy Thursday Option Activity: RIOT, ABBV, INVH | ABBV | https://www.nasdaq.com/articles/noteworthy-thursday-option-activity%3A-riot-abbv-invh | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Riot Blockchain Inc (Symbol: RIOT), where a total volume of 90,462 contracts has been traded thus far today, a contract volume which is representative of approximately 9.0 million underlying shares (giv... | Particularly high volume was seen for the $155 strike call option expiring July 29, 2022, with 9,400 contracts trading so far today, representing approximately 940,000 underlying shares of ABBV. Below is a chart showing RIOT's trailing twelve month trading history, with the $7.50 strike highlighted in orange: AbbVie In... | Below is a chart showing RIOT's trailing twelve month trading history, with the $7.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,701 contracts, representing approximately 2.6 million underlying shares or approximately 48.7% of ABBV's average daily trading volume over the pa... | Below is a chart showing RIOT's trailing twelve month trading history, with the $7.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,701 contracts, representing approximately 2.6 million underlying shares or approximately 48.7% of ABBV's average daily trading volume over the pa... | Below is a chart showing RIOT's trailing twelve month trading history, with the $7.50 strike highlighted in orange: AbbVie Inc (Symbol: ABBV) saw options trading volume of 25,701 contracts, representing approximately 2.6 million underlying shares or approximately 48.7% of ABBV's average daily trading volume over the pa... |
23,221 | 2022-07-28 00:00:00 UTC | Here's How Long It Could Realistically Take to Turn $25,000 Into $1 Million | ABBV | https://www.nasdaq.com/articles/heres-how-long-it-could-realistically-take-to-turn-%2425000-into-%241-million | null | null | Betting on crypto and meme stocks has made many people rich, but it's also caused significant losses for those who haven't been as lucky. Investing for the long term is safer, and it's much more likely that you'll end up with a big profit in the end. There's no sugar-coating it: It does require patience. And below, I'l... | Another top drugmaker, AbbVie, has also achieved impressive total returns of 160% over the same period. This includes Eli Lilly, AbbVie, and other top healthcare stocks like Johnson & Johnson and UnitedHealth Group. Betting on crypto and meme stocks has made many people rich, but it's also caused significant losses for... | This includes Eli Lilly, AbbVie, and other top healthcare stocks like Johnson & Johnson and UnitedHealth Group. Another top drugmaker, AbbVie, has also achieved impressive total returns of 160% over the same period. During the past five years, the Health Care Select Sector SPDR has generated returns comparable to those... | This includes Eli Lilly, AbbVie, and other top healthcare stocks like Johnson & Johnson and UnitedHealth Group. Another top drugmaker, AbbVie, has also achieved impressive total returns of 160% over the same period. 10 stocks we like better than Health Care SPDR When our award-winning analyst team has a stock tip, it c... | Another top drugmaker, AbbVie, has also achieved impressive total returns of 160% over the same period. This includes Eli Lilly, AbbVie, and other top healthcare stocks like Johnson & Johnson and UnitedHealth Group. Achieving high growth rates can be difficult over the long term (especially while also keeping your risk... |
23,222 | 2022-07-28 00:00:00 UTC | Pfizer (PFE) Q2 Earnings and Revenues Surpass Estimates | ABBV | https://www.nasdaq.com/articles/pfizer-pfe-q2-earnings-and-revenues-surpass-estimates | null | null | Pfizer (PFE) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.75 per share. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 16.57%. A quarter ago, it was e... | Another stock from the same industry, AbbVie (ABBV), has yet to report results for the quarter ended June 2022. AbbVie's revenues are expected to be $14.65 billion, up 5% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report | Another stock from the same industry, AbbVie (ABBV), has yet to report results for the quarter ended June 2022. AbbVie's revenues are expected to be $14.65 billion, up 5% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report | Another stock from the same industry, AbbVie (ABBV), has yet to report results for the quarter ended June 2022. AbbVie's revenues are expected to be $14.65 billion, up 5% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report | Another stock from the same industry, AbbVie (ABBV), has yet to report results for the quarter ended June 2022. AbbVie's revenues are expected to be $14.65 billion, up 5% from the year-ago quarter. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,223 | 2022-07-28 00:00:00 UTC | Pre-Market Earnings Report for July 29, 2022 : XOM, PG, CVX, ABBV, AZN, ENB, CHTR, CL, AON, PSX, IMO, ES | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-july-29-2022-%3A-xom-pg-cvx-abbv-azn-enb-chtr-cl-aon-psx-0 | null | null | The following companies are expected to report earnings prior to market open on 07/29/2022. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation (XOM)is reporting for the quarter ending June 30, 2022. The oil company's consensus earnings per share forecast from the 9 analy... | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.77 vs. an industry ratio of 15.90. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.77 vs. an industry ratio of 15.90. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.77 vs. an industry ratio of 15.90. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.77 vs. an industry ratio of 15.90. |
23,224 | 2022-07-28 00:00:00 UTC | Pre-Market Earnings Report for July 29, 2022 : XOM, PG, CVX, ABBV, AZN, ENB, CHTR, CL, AON, PSX, IMO, ES | ABBV | https://www.nasdaq.com/articles/pre-market-earnings-report-for-july-29-2022-%3A-xom-pg-cvx-abbv-azn-enb-chtr-cl-aon-psx-imo | null | null | The following companies are expected to report earnings prior to market open on 07/29/2022. Visit our Earnings Calendar for a full list of expected earnings releases.
Exxon Mobil Corporation (XOM)is reporting for the quarter ending June 30, 2022. The oil company's consensus earnings per share forecast from the 9 analy... | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.77 vs. an industry ratio of 15.90. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.77 vs. an industry ratio of 15.90. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.77 vs. an industry ratio of 15.90. | AbbVie Inc. (ABBV)is reporting for the quarter ending June 30, 2022. In the past year ABBV has met analyst expectations once and beat the expectations the other three quarters. Zacks Investment Research reports that the 2022 Price to Earnings ratio for ABBV is 10.77 vs. an industry ratio of 15.90. |
23,225 | 2022-07-27 00:00:00 UTC | AbbVie's Allergan reaches $2 bln opioid lawsuit settlement - Bloomberg News | ABBV | https://www.nasdaq.com/articles/abbvies-allergan-reaches-%242-bln-opioid-lawsuit-settlement-bloomberg-news | null | null | July 27 (Reuters) - AbbVie Inc's ABBV.N unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News reported on Wednesday, citing people familiar with the matter.
The deal would settle more than 3,000 lawsuits filed by ... | July 27 (Reuters) - AbbVie Inc's ABBV.N unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News reported on Wednesday, citing people familiar with the matter. AbbVie did not immediately respond to a Reuters request ... | July 27 (Reuters) - AbbVie Inc's ABBV.N unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News reported on Wednesday, citing people familiar with the matter. AbbVie did not immediately respond to a Reuters request ... | July 27 (Reuters) - AbbVie Inc's ABBV.N unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News reported on Wednesday, citing people familiar with the matter. AbbVie did not immediately respond to a Reuters request ... | July 27 (Reuters) - AbbVie Inc's ABBV.N unit Allergan has reached an agreement to pay over $2 billion to resolve thousands of lawsuits related to the marketing of its opioid painkiller, Bloomberg News reported on Wednesday, citing people familiar with the matter. AbbVie did not immediately respond to a Reuters request ... |
23,226 | 2022-07-27 00:00:00 UTC | Noteworthy ETF Outflows: IVE, BMY, T, ABBV | ABBV | https://www.nasdaq.com/articles/noteworthy-etf-outflows%3A-ive-bmy-t-abbv | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Value ETF (Symbol: IVE) where we have detected an approximate $218.5 million dollar outflow -- that's a 0.9% decrease week over week (from 169,150,000 to 167,600,000). Among ... | Among the largest underlying components of IVE, in trading today Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.1%, AT&T Inc (Symbol: T) is up about 0.3%, and AbbVie Inc (Symbol: ABBV) is lower by about 1%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price p... | Among the largest underlying components of IVE, in trading today Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.1%, AT&T Inc (Symbol: T) is up about 0.3%, and AbbVie Inc (Symbol: ABBV) is lower by about 1%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price p... | Among the largest underlying components of IVE, in trading today Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.1%, AT&T Inc (Symbol: T) is up about 0.3%, and AbbVie Inc (Symbol: ABBV) is lower by about 1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... | Among the largest underlying components of IVE, in trading today Bristol Myers Squibb Co. (Symbol: BMY) is down about 0.1%, AT&T Inc (Symbol: T) is up about 0.3%, and AbbVie Inc (Symbol: ABBV) is lower by about 1%. For a complete list of holdings, visit the IVE Holdings page » The chart below shows the one year price p... |
23,227 | 2022-07-27 00:00:00 UTC | Merck avoided billions in U.S. tax by offshoring Keytruda profits - senator | ABBV | https://www.nasdaq.com/articles/merck-avoided-billions-in-u.s.-tax-by-offshoring-keytruda-profits-senator | null | null | By Michael Erman
July 27 (Reuters) - Drugmaker Merck & Co MRK.N avoided billions of dollars of U.S. taxes in recent years on its top-selling cancer drug Keytruda by booking all the profits from the treatment outside of the United States, according to an ongoing investigation by Democrats on the Senate Finance Committee... | Democrats on the committee have been investigating how the tax law passed by Republicans in 2017 has benefited large U.S. pharmaceutical companies such as Merck and AbbVie and whether those companies have been exploiting foreign subsidiaries to avoid taxes. AbbVie did not immediately respond to a request for comment. E... | Democrats on the committee have been investigating how the tax law passed by Republicans in 2017 has benefited large U.S. pharmaceutical companies such as Merck and AbbVie and whether those companies have been exploiting foreign subsidiaries to avoid taxes. AbbVie did not immediately respond to a request for comment. E... | Democrats on the committee have been investigating how the tax law passed by Republicans in 2017 has benefited large U.S. pharmaceutical companies such as Merck and AbbVie and whether those companies have been exploiting foreign subsidiaries to avoid taxes. AbbVie did not immediately respond to a request for comment. E... | Democrats on the committee have been investigating how the tax law passed by Republicans in 2017 has benefited large U.S. pharmaceutical companies such as Merck and AbbVie and whether those companies have been exploiting foreign subsidiaries to avoid taxes. AbbVie did not immediately respond to a request for comment. E... |
23,228 | 2022-07-27 00:00:00 UTC | AbbVie Submits Regulatory Applications To FDA, EMA For Upadacitinib For Crohn's Disease In Adults | ABBV | https://www.nasdaq.com/articles/abbvie-submits-regulatory-applications-to-fda-ema-for-upadacitinib-for-crohns-disease-in | null | null | (RTTNews) - AbbVie (ABBV) Wednesday said it has submitted regulatory applications for a new indication for upadacitinib or RINVOQ, 45 mg, induction dose, and 15 mg and 30 mg, maintenance dose. The submissions are supported by phase 3 clinical trial, two induction studies and one maintenance study.
According to AbbVie, ... | According to AbbVie, upadacitinib achieved the co-primary endpoints of clinical remission and endoscopic response. (RTTNews) - AbbVie (ABBV) Wednesday said it has submitted regulatory applications for a new indication for upadacitinib or RINVOQ, 45 mg, induction dose, and 15 mg and 30 mg, maintenance dose. The applicat... | (RTTNews) - AbbVie (ABBV) Wednesday said it has submitted regulatory applications for a new indication for upadacitinib or RINVOQ, 45 mg, induction dose, and 15 mg and 30 mg, maintenance dose. According to AbbVie, upadacitinib achieved the co-primary endpoints of clinical remission and endoscopic response. The submissi... | (RTTNews) - AbbVie (ABBV) Wednesday said it has submitted regulatory applications for a new indication for upadacitinib or RINVOQ, 45 mg, induction dose, and 15 mg and 30 mg, maintenance dose. According to AbbVie, upadacitinib achieved the co-primary endpoints of clinical remission and endoscopic response. The applicat... | (RTTNews) - AbbVie (ABBV) Wednesday said it has submitted regulatory applications for a new indication for upadacitinib or RINVOQ, 45 mg, induction dose, and 15 mg and 30 mg, maintenance dose. According to AbbVie, upadacitinib achieved the co-primary endpoints of clinical remission and endoscopic response. The submissi... |
23,229 | 2022-07-27 00:00:00 UTC | 3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off | ABBV | https://www.nasdaq.com/articles/3-supercharged-dividend-stocks-to-buy-if-theres-a-stock-market-sell-off-1 | null | null | When there's a market sell-off -- like in recent times -- it's a good idea to have a few dividend stocks in your portfolio. Why? Because they'll provide you with steady income even if the market continues to decline. And in better times, you'll appreciate this recurrent income too.
Today, three healthcare players have ... | I'm talking about AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Cardinal Health (NYSE: CAH). AbbVie AbbVie's dividend payments have more than doubled over the past five years. AbbVie has lifted its dividend for the past 50 years, making it a Dividend King. | I'm talking about AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Cardinal Health (NYSE: CAH). AbbVie AbbVie's dividend payments have more than doubled over the past five years. AbbVie has lifted its dividend for the past 50 years, making it a Dividend King. | AbbVie has lifted its dividend for the past 50 years, making it a Dividend King. I'm talking about AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Cardinal Health (NYSE: CAH). AbbVie AbbVie's dividend payments have more than doubled over the past five years. | But you'll want to own AbbVie for more than just its dividend. I'm talking about AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), and Cardinal Health (NYSE: CAH). AbbVie AbbVie's dividend payments have more than doubled over the past five years. |
23,230 | 2022-07-26 00:00:00 UTC | Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | ABBV | https://www.nasdaq.com/articles/teva-reaches-proposed-%244.35-bln-settlement-of-u.s.-opioid-lawsuits-0 | null | null | By Dietrich Knauth and Nate Raymond
July 26 (Reuters) - Teva Pharmaceutical Industries TEVA.TA on Tuesday announced a $4.35 billion proposed nationwide settlement that could resolve thousands of lawsuits over the drugmaker's alleged role in the U.S. opioid epidemic.
The proposal calls for Teva to pay state and local go... | Teva's settlement is contingent on separate settlements by AbbVie's ABBV.N Allergan unit. By Dietrich Knauth and Nate Raymond July 26 (Reuters) - Teva Pharmaceutical Industries TEVA.TA on Tuesday announced a $4.35 billion proposed nationwide settlement that could resolve thousands of lawsuits over the drugmaker's alleg... | Teva's settlement is contingent on separate settlements by AbbVie's ABBV.N Allergan unit. The proposal calls for Teva to pay state and local governments up to $3.7 billion in cash over 13 years plus a contribution of $1.2 billion worth of the opioid overdose reversal drug naloxone. CEO Kare Schultz told analysts at the... | Teva's settlement is contingent on separate settlements by AbbVie's ABBV.N Allergan unit. The proposal calls for Teva to pay state and local governments up to $3.7 billion in cash over 13 years plus a contribution of $1.2 billion worth of the opioid overdose reversal drug naloxone. For the Teva deal to take effect, All... | Teva's settlement is contingent on separate settlements by AbbVie's ABBV.N Allergan unit. The proposal calls for Teva to pay state and local governments up to $3.7 billion in cash over 13 years plus a contribution of $1.2 billion worth of the opioid overdose reversal drug naloxone. For the Teva deal to take effect, All... |
23,231 | 2022-07-26 00:00:00 UTC | Teva reaches proposed $4.35 bln settlement of U.S. opioid lawsuits | ABBV | https://www.nasdaq.com/articles/teva-reaches-proposed-%244.35-bln-settlement-of-u.s.-opioid-lawsuits | null | null | By Dietrich Knauth and Nate Raymond
July 26 (Reuters) - Teva Pharmaceutical Industries TEVA.TA on Tuesday announced a $4.35 billion proposed nationwide settlement that could resolve thousands of lawsuits over the drugmaker's alleged role in the U.S. opioid epidemic.
The proposal calls for Teva to pay up to $3.7 billion... | Teva's settlement is contingent on separate settlements by AbbVie's ABBV.N Allergan unit. By Dietrich Knauth and Nate Raymond July 26 (Reuters) - Teva Pharmaceutical Industries TEVA.TA on Tuesday announced a $4.35 billion proposed nationwide settlement that could resolve thousands of lawsuits over the drugmaker's alleg... | Teva's settlement is contingent on separate settlements by AbbVie's ABBV.N Allergan unit. The proposal calls for Teva to pay up to $3.7 billion in cash over 13 years and provide a company estimated $1.2 billion worth the opioid overdose reversal drug naloxone. Teva's proposed settlement would allow state and local gove... | Teva's settlement is contingent on separate settlements by AbbVie's ABBV.N Allergan unit. The proposal calls for Teva to pay up to $3.7 billion in cash over 13 years and provide a company estimated $1.2 billion worth the opioid overdose reversal drug naloxone. For the Teva deal to take effect, Allergan must reach its o... | Teva's settlement is contingent on separate settlements by AbbVie's ABBV.N Allergan unit. Teva's proposed settlement would allow state and local governments to opt for additional cash in lieu of an allotment of the overdose medication, at a value of 20% of the drug's list price. CEO Kare Schultz told analysts at the ti... |
23,232 | 2022-07-26 00:00:00 UTC | AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-to-report-q2-earnings%3A-whats-in-the-cards | null | null | AbbVie ABBV will report second-quarter 2022 results on Jul 29, before market open. In the last reported quarter, the company delivered an earnings surprise of 0.32%.
AbbVie’s stock has risen 11% so far this year compared with an increase of 2.8% for the industry.
Image Source: Zacks Investment Research
This large drug... | On theearnings call investors’ focus will likely be on AbbVie’s strategies around Humira following its potential loss of exclusivity in the United States, which is expected next year. AbbVie ABBV will report second-quarter 2022 results on Jul 29, before market open. AbbVie’s stock has risen 11% so far this year compare... | AbbVie ABBV will report second-quarter 2022 results on Jul 29, before market open. AbbVie’s stock has risen 11% so far this year compared with an increase of 2.8% for the industry. ABBV expects adjusted revenues to be around $14.6 billion in the second quarter, indicating year-over-year growth of nearly 5%. | AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Stocks to Consider Here are some large drug/biotech stocks that have the right combination of elements to beat on earnings this time around: AstraZeneca AZN has an Earnings ESP of +1.38% and a Zacks Rank #3. AbbVie ABBV will report second-quarter 2022 results on J... | AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Stocks to Consider Here are some large drug/biotech stocks that have the right combination of elements to beat on earnings this time around: AstraZeneca AZN has an Earnings ESP of +1.38% and a Zacks Rank #3. AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie AB... |
23,233 | 2022-07-26 00:00:00 UTC | European Commission Approves AbbVie's Rinvoq To Treat Moderate To Severe Ulcerative Colitis | ABBV | https://www.nasdaq.com/articles/european-commission-approves-abbvies-rinvoq-to-treat-moderate-to-severe-ulcerative-colitis | null | null | (RTTNews) - The European Commission approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, AbbVie (ABBV) s... | (RTTNews) - The European Commission approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, AbbVie (ABBV) s... | (RTTNews) - The European Commission approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, AbbVie (ABBV) s... | (RTTNews) - The European Commission approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, AbbVie (ABBV) s... | (RTTNews) - The European Commission approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent, AbbVie (ABBV) s... |
23,234 | 2022-07-25 00:00:00 UTC | Will Merck Stock Rise After Its Q2 Results? | ABBV | https://www.nasdaq.com/articles/will-merck-stock-rise-after-its-q2-results | null | null | Merck (NYSE: MRK) is scheduled to report its Q2 2022 results on Thursday, July 28. We expect the company to have a robust Q2, with revenue falling in-line and earnings expected to be slightly above the consensus estimates, driven by a continued uptick in sales of its key drugs, including Keytruda, Lagevrio, and Gardasi... | The company’s overall revenue growth is likely bolstered by market share gains for Keytruda and Gardasil and its Covid-19 treatment – Lagevrio. (3) MRK stock has only a little room for growth We estimate Merck’s Valuation to be $99 per share, which is only 10% above the current market price of $90. This represents a fo... | (1) Revenues expected to be in line with the consensus estimates Trefis estimates Merck’s Q2 2022 revenues to be $13.9 billion, aligning with the consensus estimate. Looking at Q1 2022, Merck reported revenue of $15.9 billion, reflecting a significant 50% y-o-y growth, partly due to a $3.2 billion sales contribution fr... | (1) Revenues expected to be in line with the consensus estimates Trefis estimates Merck’s Q2 2022 revenues to be $13.9 billion, aligning with the consensus estimate. (2) EPS expected to be slightly above the consensus estimates Merck’s Q2 2022 adjusted earnings per share (EPS) is expected to be $1.73 per Trefis analysi... | (2) EPS expected to be slightly above the consensus estimates Merck’s Q2 2022 adjusted earnings per share (EPS) is expected to be $1.73 per Trefis analysis, slightly above the consensus estimate of $1.69. (3) MRK stock has only a little room for growth We estimate Merck’s Valuation to be $99 per share, which is only 10... |
23,235 | 2022-07-25 00:00:00 UTC | 3 Dividend Kings Suited Perfectly for Income Investors | ABBV | https://www.nasdaq.com/articles/3-dividend-kings-suited-perfectly-for-income-investors | null | null | Income investing is a widely-deployed strategy within the market. After all, there are few things in life sweeter than getting paid.
Companies that consistently increase their dividend payouts are well-established in nature with successful business operations. In addition, they tend to carry a lower level of risk, undo... | Three companies – Coca-Cola KO, Emerson Electric EMR, and AbbVie Inc. ABBV – are all part of the elite Dividend King group. AbbVie AbbVie ABBV is a global research-based biopharmaceutical company that delivers innovative medicines. AbbVie’s dividend metrics might be the most robust of them all. | Image Source: Zacks Investment Research Undoubtedly a major positive, AbbVie has consistently reported bottom-line results above expectations, exceeding the Zacks Consensus EPS Estimate in nine of its previous ten quarterly reports. Three companies – Coca-Cola KO, Emerson Electric EMR, and AbbVie Inc. ABBV – are all pa... | AbbVie has just joined the elite Dividend King group – the company has increased its annual dividend for 50 consecutive years. Image Source: Zacks Investment Research Undoubtedly a major positive, AbbVie has consistently reported bottom-line results above expectations, exceeding the Zacks Consensus EPS Estimate in nine... | Three companies – Coca-Cola KO, Emerson Electric EMR, and AbbVie Inc. ABBV – are all part of the elite Dividend King group. AbbVie has just joined the elite Dividend King group – the company has increased its annual dividend for 50 consecutive years. Image Source: Zacks Investment Research Undoubtedly a major positive,... |
23,236 | 2022-07-25 00:00:00 UTC | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | ABBV | https://www.nasdaq.com/articles/here-is-what-to-know-beyond-why-abbvie-inc.-abbv-is-a-trending-stock-0 | null | null | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this drugmaker have returned -2.5%, compared to the Zacks S&P 500 composite's +5.... | Conclusion The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals indus... | For the next fiscal year, the consensus earnings estimate of $11.84 indicates a change of -14.7% from what AbbVie is expected to report a year ago. AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which AbbVie falls in, ha... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which Abb... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #3 (Hold). AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. During this period, the Zacks Large Cap Pharmaceuticals industry, which Abb... |
23,237 | 2022-07-25 00:00:00 UTC | The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights-jj-novartis-gsk-merck-and-abbvie | null | null | For Immediate Release
Chicago, IL – July 25, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: J&J JNJ, Novartis NVS, GSK pl... | Merck's head and neck cancer study on Keytruda failed while AbbVie filed a regulatory application in Europe seeking approval for its migraine candidate atogepant. Stocks recently featured in the blog include: J&J JNJ, Novartis NVS, GSK plc GSK, Merck MRK and AbbVie ABBV. AbbVie Seeks Approval for Migraine Candidate in ... | Stocks recently featured in the blog include: J&J JNJ, Novartis NVS, GSK plc GSK, Merck MRK and AbbVie ABBV. Merck's head and neck cancer study on Keytruda failed while AbbVie filed a regulatory application in Europe seeking approval for its migraine candidate atogepant. AbbVie Seeks Approval for Migraine Candidate in ... | Stocks recently featured in the blog include: J&J JNJ, Novartis NVS, GSK plc GSK, Merck MRK and AbbVie ABBV. Merck's head and neck cancer study on Keytruda failed while AbbVie filed a regulatory application in Europe seeking approval for its migraine candidate atogepant. AbbVie Seeks Approval for Migraine Candidate in ... | Stocks recently featured in the blog include: J&J JNJ, Novartis NVS, GSK plc GSK, Merck MRK and AbbVie ABBV. Merck's head and neck cancer study on Keytruda failed while AbbVie filed a regulatory application in Europe seeking approval for its migraine candidate atogepant. AbbVie Seeks Approval for Migraine Candidate in ... |
23,238 | 2022-07-24 00:00:00 UTC | 7 Value Stocks Trading at a Massive Discount Right Now | ABBV | https://www.nasdaq.com/articles/7-value-stocks-trading-at-a-massive-discount-right-now | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Value stocks have underperformed growth stocks over the past decade or so. This is due to the cheap financing available to hyper-growth businesses. Moreover, investors employed a risk-on approach towards stock picking. However, the tables have turned this y... | EXPE Expedia $Expedia ABBV AbbVie $148.55 TGT Target $159.2 LEG Leggett & Platt $39.1 BCS Barclays $7.68 URI United Rentals $280 DHI D.R. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a leading global pharmaceutical company that commercializes and develops some of the biggest moneymakers in ... | EXPE Expedia $Expedia ABBV AbbVie $148.55 TGT Target $159.2 LEG Leggett & Platt $39.1 BCS Barclays $7.68 URI United Rentals $280 DHI D.R. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a leading global pharmaceutical company that commercializes and develops some of the biggest moneymakers in ... | EXPE Expedia $Expedia ABBV AbbVie $148.55 TGT Target $159.2 LEG Leggett & Platt $39.1 BCS Barclays $7.68 URI United Rentals $280 DHI D.R. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a leading global pharmaceutical company that commercializes and develops some of the biggest moneymakers in ... | EXPE Expedia $Expedia ABBV AbbVie $148.55 TGT Target $159.2 LEG Leggett & Platt $39.1 BCS Barclays $7.68 URI United Rentals $280 DHI D.R. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE:ABBV) is a leading global pharmaceutical company that commercializes and develops some of the biggest moneymakers in ... |
23,239 | 2022-07-22 00:00:00 UTC | Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off | ABBV | https://www.nasdaq.com/articles/pharma-stock-roundup%3A-jnj-nvs-q2-earnings-gsk-consumer-unit-spin-off | null | null | This week, J&J JNJ set in motion the second-quarter earnings season for the drug and biotech sector with an earnings and sales beat. Novartis NVS reported mixed results. GSK plc GSK completed the separation of its Consumer Healthcare (CHC) segment into a new company, Haleon. Merck’s (MRK) head and neck cancer study on ... | Merck’s (MRK) head and neck cancer study on Keytruda failed while AbbVie ABBV filed a regulatory application in Europe seeking approval for its migraine candidate atogepant. AbbVie Seeks Approval for Migraine Candidate in Europe: AbbVie submitted a marketing authorization application (MAA) to the European Medicines Age... | Merck’s (MRK) head and neck cancer study on Keytruda failed while AbbVie ABBV filed a regulatory application in Europe seeking approval for its migraine candidate atogepant. AbbVie Seeks Approval for Migraine Candidate in Europe: AbbVie submitted a marketing authorization application (MAA) to the European Medicines Age... | Merck’s (MRK) head and neck cancer study on Keytruda failed while AbbVie ABBV filed a regulatory application in Europe seeking approval for its migraine candidate atogepant. AbbVie Seeks Approval for Migraine Candidate in Europe: AbbVie submitted a marketing authorization application (MAA) to the European Medicines Age... | Merck’s (MRK) head and neck cancer study on Keytruda failed while AbbVie ABBV filed a regulatory application in Europe seeking approval for its migraine candidate atogepant. AbbVie Seeks Approval for Migraine Candidate in Europe: AbbVie submitted a marketing authorization application (MAA) to the European Medicines Age... |
23,240 | 2022-07-22 00:00:00 UTC | Zacks Value Investor Highlights: Merck, Maravai LifeSciences, Sensus Healthcare, PetIQ and AbbVie | ABBV | https://www.nasdaq.com/articles/zacks-value-investor-highlights%3A-merck-maravai-lifesciences-sensus-healthcare-petiq-and | null | null | For Immediate Release
Chicago, IL – July 22, 2022 – Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life. To listen to the podcast, click here: h... | (6:00) - Tracey’s Top Stock Picks (19:50) - Episode Roundup: MRK, MRVI, SRTS, PETQ, ABBV Podcast@Zacks.com Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks. AbbVie (ABBV) AbbVie is a large cap pharmaceutical company that owns Humira and... | (6:00) - Tracey’s Top Stock Picks (19:50) - Episode Roundup: MRK, MRVI, SRTS, PETQ, ABBV Podcast@Zacks.com Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks. AbbVie (ABBV) AbbVie is a large cap pharmaceutical company that owns Humira and... | (6:00) - Tracey’s Top Stock Picks (19:50) - Episode Roundup: MRK, MRVI, SRTS, PETQ, ABBV Podcast@Zacks.com Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks. AbbVie (ABBV) AbbVie is a large cap pharmaceutical company that owns Humira and... | (6:00) - Tracey’s Top Stock Picks (19:50) - Episode Roundup: MRK, MRVI, SRTS, PETQ, ABBV Podcast@Zacks.com Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares some of her top value investing tips and stock picks. AbbVie (ABBV) AbbVie is a large cap pharmaceutical company that owns Humira and... |
23,241 | 2022-07-22 00:00:00 UTC | Could AbbVie Stock Help You Retire a Millionaire? | ABBV | https://www.nasdaq.com/articles/could-abbvie-stock-help-you-retire-a-millionaire-0 | null | null | Finding a good group of stocks to invest in for the long haul can be part of a sound strategy in getting your portfolio to be worth $1 million. The more you invest, the easier it'll be to reach that target. One way to maximize your odds for success is by investing in stocks that are both growing and pay dividends.
One ... | AbbVie is facing that situation today as its hugely successful rheumatoid arthritis drug Humira will lose patent protection next year. It wouldn't be surprising for that trend to continue, as AbbVie has a bright future ahead and is generating tons of cash flow that can help it pursue more growth opportunities if it nee... | There's certainly no cause for concern today: AbbVie reported more than $22 billion in free cash flow over the trailing 12 months (versus dividend payments of $9.5 billion). Over the past decade, AbbVie's total returns (including dividends) have totaled 538% -- far higher than the S&P 500's returns of just 227%. One po... | There are no guarantees when it comes to dividends, but as AbbVie is a Dividend King, it has a strong track record, and as long as the business continues generating strong results, those rate hikes are likely to continue. Given the company's growth potential and high-yielding dividends, there's definitely a path for an... | One potential option is drugmaker AbbVie (NYSE: ABBV). AbbVie is facing that situation today as its hugely successful rheumatoid arthritis drug Humira will lose patent protection next year. However, with the help of AbbVie's pipeline, the company can help find ways to make up for those declines. |
23,242 | 2022-07-21 00:00:00 UTC | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-but-lags-market%3A-what-you-should-know-4 | null | null | AbbVie (ABBV) closed at $147.75 in the latest trading session, marking a +0.04% move from the prior day. The stock lagged the S&P 500's daily gain of 0.99%. Elsewhere, the Dow gained 0.51%, while the tech-heavy Nasdaq lost 0.31%.
Coming into today, shares of the drugmaker had gained 0.09% in the past month. In that sam... | AbbVie (ABBV) closed at $147.75 in the latest trading session, marking a +0.04% move from the prior day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $13.88 per share and revenue of $59.61 billion. AbbVie will be looking to display strength as it nears its next earnings release, which is expec... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $13.88 per share and revenue of $59.61 billion. AbbVie (ABBV) closed at $147.75 in the latest trading session, marking a +0.04% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is expec... | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $13.88 per share and revenue of $59.61 billion. AbbVie (ABBV) closed at $147.75 in the latest trading session, marking a +0.04% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is expec... | AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie (ABBV) closed at $147.75 in the latest trading session, marking a +0.04% move from the prior day. AbbVie will be looking to display strength as it nears its next earnings release, which is expected to be July 29, 2022. |
23,243 | 2022-07-21 00:00:00 UTC | 5 Cheap Healthcare Stocks in 2022 | ABBV | https://www.nasdaq.com/articles/5-cheap-healthcare-stocks-in-2022 | null | null | (0:45) - Are There Value Stocks In The Healthcare Sector?
(6:00) - Tracey’s Top Stock Picks
(19:50) - Episode Roundup: MRK, MRVI, SRTS, PETQ, ABBV
Podcast@Zacks.com
Welcome to Episode #290 of the Value Investor Podcast.
Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio, shares so... | (6:00) - Tracey’s Top Stock Picks (19:50) - Episode Roundup: MRK, MRVI, SRTS, PETQ, ABBV Podcast@Zacks.com Welcome to Episode #290 of the Value Investor Podcast. AbbVie ABBV AbbVie is a large cap pharmaceutical company that owns Humira and popular aesthetic drugs Botox and Juvederm. AbbVie shares are up about 10% year-... | (6:00) - Tracey’s Top Stock Picks (19:50) - Episode Roundup: MRK, MRVI, SRTS, PETQ, ABBV Podcast@Zacks.com Welcome to Episode #290 of the Value Investor Podcast. AbbVie ABBV AbbVie is a large cap pharmaceutical company that owns Humira and popular aesthetic drugs Botox and Juvederm. AbbVie shares are up about 10% year-... | (6:00) - Tracey’s Top Stock Picks (19:50) - Episode Roundup: MRK, MRVI, SRTS, PETQ, ABBV Podcast@Zacks.com Welcome to Episode #290 of the Value Investor Podcast. AbbVie ABBV AbbVie is a large cap pharmaceutical company that owns Humira and popular aesthetic drugs Botox and Juvederm. AbbVie shares are up about 10% year-... | (6:00) - Tracey’s Top Stock Picks (19:50) - Episode Roundup: MRK, MRVI, SRTS, PETQ, ABBV Podcast@Zacks.com Welcome to Episode #290 of the Value Investor Podcast. AbbVie ABBV AbbVie is a large cap pharmaceutical company that owns Humira and popular aesthetic drugs Botox and Juvederm. AbbVie shares are up about 10% year-... |
23,244 | 2022-07-21 00:00:00 UTC | Healthcare ETFs in Focus Ahead of Q2 Earnings | ABBV | https://www.nasdaq.com/articles/healthcare-etfs-in-focus-ahead-of-q2-earnings | null | null | The healthcare sector has gained some momentum lately on investors’ rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio. Additionally, recession fears have raised the appeal for defensive bets.
As such, the ultra-popular ETFs, Health C... | The further price movement of these funds depends on earnings releases from some big names like Pfizer PFE, Merck MRK, Amgen AMGN, AbbVie ABBV, Bristol Myers Squibb BMY and Eli Liily LLY that dominate returns. AbbVie has a Zacks Rank #3 and an Earnings ESP of +1.45%. AbbVie Inc. (ABBV): Free Stock Analysis Report | The further price movement of these funds depends on earnings releases from some big names like Pfizer PFE, Merck MRK, Amgen AMGN, AbbVie ABBV, Bristol Myers Squibb BMY and Eli Liily LLY that dominate returns. AbbVie has a Zacks Rank #3 and an Earnings ESP of +1.45%. AbbVie Inc. (ABBV): Free Stock Analysis Report | The further price movement of these funds depends on earnings releases from some big names like Pfizer PFE, Merck MRK, Amgen AMGN, AbbVie ABBV, Bristol Myers Squibb BMY and Eli Liily LLY that dominate returns. AbbVie has a Zacks Rank #3 and an Earnings ESP of +1.45%. AbbVie Inc. (ABBV): Free Stock Analysis Report | The further price movement of these funds depends on earnings releases from some big names like Pfizer PFE, Merck MRK, Amgen AMGN, AbbVie ABBV, Bristol Myers Squibb BMY and Eli Liily LLY that dominate returns. AbbVie has a Zacks Rank #3 and an Earnings ESP of +1.45%. AbbVie Inc. (ABBV): Free Stock Analysis Report |
23,245 | 2022-07-21 00:00:00 UTC | 3 Steps You'll Regret Not Taking During This Bear Market | ABBV | https://www.nasdaq.com/articles/3-steps-youll-regret-not-taking-during-this-bear-market | null | null | If your portfolio is teetering amid a turbulent bear market -- as pretty much everyone's is at the moment -- you need a plan to come out ahead, and you need to act on it. Fruitful investments made today could have the benefit of a very long run-up once the bear market subsides, and mistakes made out of fear could have ... | Take the returns from AbbVie (NYSE: ABBV) over the last 10 years, for example: ABBV data by YCharts As the chart shows, the price returns from AbbVie shares are nowhere near the total return that's possible by retaining and reinvesting each of its quarterly dividend payments. Plus, biopharma companies like AbbVie often... | Take the returns from AbbVie (NYSE: ABBV) over the last 10 years, for example: ABBV data by YCharts As the chart shows, the price returns from AbbVie shares are nowhere near the total return that's possible by retaining and reinvesting each of its quarterly dividend payments. Plus, biopharma companies like AbbVie often... | Take the returns from AbbVie (NYSE: ABBV) over the last 10 years, for example: ABBV data by YCharts As the chart shows, the price returns from AbbVie shares are nowhere near the total return that's possible by retaining and reinvesting each of its quarterly dividend payments. Plus, biopharma companies like AbbVie often... | Take the returns from AbbVie (NYSE: ABBV) over the last 10 years, for example: ABBV data by YCharts As the chart shows, the price returns from AbbVie shares are nowhere near the total return that's possible by retaining and reinvesting each of its quarterly dividend payments. Plus, biopharma companies like AbbVie often... |
23,246 | 2022-07-20 00:00:00 UTC | Pre-Market Most Active for Jul 20, 2022 : SDIG, APLD, TQQQ, SQQQ, SNTI, QQQ, CCL, ABT, NIO, ABBV, NCLH, F | ABBV | https://www.nasdaq.com/articles/pre-market-most-active-for-jul-20-2022-%3A-sdig-apld-tqqq-sqqq-snti-qqq-ccl-abt-nio-abbv | null | null | The NASDAQ 100 Pre-Market Indicator is down -17.24 to 12,232.18. The total Pre-Market volume is currently 57,213,766 shares traded.
The following are the most active stocks for the pre-market session:
Stronghold Digital Mining, Inc. (SDIG) is +0.58 at $2.72, with 8,872,950 shares traded. As reported by Zacks, the cur... | AbbVie Inc. (ABBV) is -0.24 at $149.50, with 443,571 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". Smarter Analyst Reports: Abbott Rewards Shareholders; Shares Record New All-Time High | As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". AbbVie Inc. (ABBV) is -0.24 at $149.50, with 443,571 shares traded. As reported by Zacks, the current mean recommendation for APLD is in the "buy range". | AbbVie Inc. (ABBV) is -0.24 at $149.50, with 443,571 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". The total Pre-Market volume is currently 57,213,766 shares traded. | AbbVie Inc. (ABBV) is -0.24 at $149.50, with 443,571 shares traded. As reported by Zacks, the current mean recommendation for ABBV is in the "buy range". As reported by Zacks, the current mean recommendation for SDIG is in the "strong buy range". |
23,247 | 2022-07-20 00:00:00 UTC | AbbVie To Collaborate With ISTAR Medical; To Pay $60 Mln To Further Develop MINIject | ABBV | https://www.nasdaq.com/articles/abbvie-to-collaborate-with-istar-medical-to-pay-%2460-mln-to-further-develop-miniject | null | null | (RTTNews) - AbbVie (ABBV) on Wednesday said it signed an alliance with iSTAR Medical SA, a Belgian medtech firm, to further develop and commercialize iSTAR's MINIject, a minimally invasive glaucoma surgical device.
As per the agreement, iSTAR will receive a $60 million in non-dilutive upfront payment. iSTAR will contin... | In addition, AbbVie will hold the exclusive right to acquire iSTAR and lead subsequent global development and commercialization of the MINIject device. The collaboration is also an opportunity to expand AbbVie's eye care business, building on its glaucoma portfolio which includes drops, sustained release implants, and ... | (RTTNews) - AbbVie (ABBV) on Wednesday said it signed an alliance with iSTAR Medical SA, a Belgian medtech firm, to further develop and commercialize iSTAR's MINIject, a minimally invasive glaucoma surgical device. In addition, AbbVie will hold the exclusive right to acquire iSTAR and lead subsequent global development... | (RTTNews) - AbbVie (ABBV) on Wednesday said it signed an alliance with iSTAR Medical SA, a Belgian medtech firm, to further develop and commercialize iSTAR's MINIject, a minimally invasive glaucoma surgical device. In addition, AbbVie will hold the exclusive right to acquire iSTAR and lead subsequent global development... | (RTTNews) - AbbVie (ABBV) on Wednesday said it signed an alliance with iSTAR Medical SA, a Belgian medtech firm, to further develop and commercialize iSTAR's MINIject, a minimally invasive glaucoma surgical device. In addition, AbbVie will hold the exclusive right to acquire iSTAR and lead subsequent global development... |
23,248 | 2022-07-20 00:00:00 UTC | 7 Best Income Stocks to Buy Now | ABBV | https://www.nasdaq.com/articles/7-best-income-stocks-to-buy-now | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While rational traders participate in the equities market to see solid returns on their investments, the present paradigm encourages everyone to consider the best income stocks to buy now. Of course, no one is going to complain about robust capital gains; T... | AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com While the vast majority of the global public is ready to put the coronavirus nightmare behind it, Nature.com reported on a concerning new phenomenon. Ticker Company Price CVX Chevron $144.61 ABBV AbbVie $149.74 Instead, concepts like retail revenge or revenge travel h... | Ticker Company Price CVX Chevron $144.61 ABBV AbbVie $149.74 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com While the vast majority of the global public is ready to put the coronavirus nightmare behind it, Nature.com reported on a concerning new phenomenon. Instead, concepts like retail revenge or revenge travel h... | The 7 Best Stocks to Buy on a Dip in July In turn, ABBV stock is one of the best income stocks to buy now — featuring a forward yield of 3.7%. Ticker Company Price CVX Chevron $144.61 ABBV AbbVie $149.74 AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com While the vast majority of the global public is ready to put the... | Ticker Company Price CVX Chevron $144.61 ABBV AbbVie $149.74 The 7 Best Stocks to Buy on a Dip in July In turn, ABBV stock is one of the best income stocks to buy now — featuring a forward yield of 3.7%. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com While the vast majority of the global public is ready to put the... |
23,249 | 2022-07-20 00:00:00 UTC | 3 High Yield Dividend Stocks To Watch Today | ABBV | https://www.nasdaq.com/articles/3-high-yield-dividend-stocks-to-watch-today | null | null | Here Are 3 Top High-Yield Dividend Stocks To Check Out Right Now
As talks of a recession continue, investors could be looking to turn to high-yield dividend stocks in the stock market today. As major indices performed poorly in the first half of the year, some investors may be searching for more conservative investment... | Best High-Yield Dividend Stocks To Watch Now Big Lots (NYSE: BIG) Altria Group (NYSE: MO) AbbVie Inc. (NYSE: ABBV) Big Lots First, up on the list, we will be taking a look at home essentials retailer, Big Lots Inc. Headquartered in Columbus, Ohio Big Lots has grown to become one of America’s leading home discount retai... | Best High-Yield Dividend Stocks To Watch Now Big Lots (NYSE: BIG) Altria Group (NYSE: MO) AbbVie Inc. (NYSE: ABBV) Big Lots First, up on the list, we will be taking a look at home essentials retailer, Big Lots Inc. Headquartered in Columbus, Ohio Big Lots has grown to become one of America’s leading home discount retai... | Best High-Yield Dividend Stocks To Watch Now Big Lots (NYSE: BIG) Altria Group (NYSE: MO) AbbVie Inc. (NYSE: ABBV) Big Lots First, up on the list, we will be taking a look at home essentials retailer, Big Lots Inc. Headquartered in Columbus, Ohio Big Lots has grown to become one of America’s leading home discount retai... | Best High-Yield Dividend Stocks To Watch Now Big Lots (NYSE: BIG) Altria Group (NYSE: MO) AbbVie Inc. (NYSE: ABBV) Big Lots First, up on the list, we will be taking a look at home essentials retailer, Big Lots Inc. Headquartered in Columbus, Ohio Big Lots has grown to become one of America’s leading home discount retai... |
23,250 | 2022-07-20 00:00:00 UTC | Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance | ABBV | https://www.nasdaq.com/articles/biogen-biib-beats-on-q2-earnings-sales-ups-2022-guidance | null | null | Biogen BIIB reported second-quarter 2022 earnings per share (EPS) of $5.25, which significantly beat the Zacks Consensus Estimate of $4.10. In the year-ago quarter, Biogen had recorded earnings of $5.25 per share.
Sales came in at $2.59 billion, down 7% on a reported basis (5% on a constant currency basis) from the yea... | Biogen Inc. Price, Consensus and EPS Surprise Biogen Inc. price-consensus-eps-surprise-chart | Biogen Inc. Quote Some better-ranked large drugmakers are Merck MRK and AbbVie ABBV. While Merck sports a Zacks Rank of 1, AbbVie has a Zacks Rank of 2 (Buy). AbbVie stock is up 10.6% this year so far. | Biogen Inc. Price, Consensus and EPS Surprise Biogen Inc. price-consensus-eps-surprise-chart | Biogen Inc. Quote Some better-ranked large drugmakers are Merck MRK and AbbVie ABBV. While Merck sports a Zacks Rank of 1, AbbVie has a Zacks Rank of 2 (Buy). AbbVie stock is up 10.6% this year so far. | Biogen Inc. Price, Consensus and EPS Surprise Biogen Inc. price-consensus-eps-surprise-chart | Biogen Inc. Quote Some better-ranked large drugmakers are Merck MRK and AbbVie ABBV. While Merck sports a Zacks Rank of 1, AbbVie has a Zacks Rank of 2 (Buy). AbbVie stock is up 10.6% this year so far. | AbbVie stock is up 10.6% this year so far. Biogen Inc. Price, Consensus and EPS Surprise Biogen Inc. price-consensus-eps-surprise-chart | Biogen Inc. Quote Some better-ranked large drugmakers are Merck MRK and AbbVie ABBV. While Merck sports a Zacks Rank of 1, AbbVie has a Zacks Rank of 2 (Buy). |
23,251 | 2022-07-19 00:00:00 UTC | 3 Dividend Growth Stocks You Can Buy Now and Hold Forever | ABBV | https://www.nasdaq.com/articles/3-dividend-growth-stocks-you-can-buy-now-and-hold-forever | null | null | Are you worried about inflation eating into your savings? Perhaps you're nervous that the Federal Reserve's plan to fight inflation with rising interest rates will lead to a recession.
At times like these, it can seem like there aren't any good options to invest in, but this isn't the case. Plenty of well-established b... | This is a great dividend growth stock to buy now because AbbVie has expertly invested its Humira profits into cash-generating machines that will more than offset those pending sales declines. AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company that was spun off from Abbott Laboratories in 2013. AbbVie's lead prod... | AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company that was spun off from Abbott Laboratories in 2013. AbbVie's lead product, Humira, was the world's top-selling drug in 2020, and second only to Pfizer's COVID-19 vaccine in 2021. This is a great dividend growth stock to buy now because AbbVie has expertly invest... | AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company that was spun off from Abbott Laboratories in 2013. AbbVie's lead product, Humira, was the world's top-selling drug in 2020, and second only to Pfizer's COVID-19 vaccine in 2021. This is a great dividend growth stock to buy now because AbbVie has expertly invest... | AbbVie AbbVie (NYSE: ABBV) is a biopharmaceutical company that was spun off from Abbott Laboratories in 2013. AbbVie's lead product, Humira, was the world's top-selling drug in 2020, and second only to Pfizer's COVID-19 vaccine in 2021. This is a great dividend growth stock to buy now because AbbVie has expertly invest... |
23,252 | 2022-07-19 00:00:00 UTC | IVW, LLY, TMO, ABBV: Large Inflows Detected at ETF | ABBV | https://www.nasdaq.com/articles/ivw-lly-tmo-abbv%3A-large-inflows-detected-at-etf | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $86.7 million dollar inflow -- that's a 0.3% increase week over week in outstanding units (from 466,050,000 to ... | Among the largest underlying components of IVW, in trading today Eli Lilly (Symbol: LLY) is up about 1.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.8%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year... | Among the largest underlying components of IVW, in trading today Eli Lilly (Symbol: LLY) is up about 1.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.8%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year... | Among the largest underlying components of IVW, in trading today Eli Lilly (Symbol: LLY) is up about 1.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.8%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ... | Among the largest underlying components of IVW, in trading today Eli Lilly (Symbol: LLY) is up about 1.1%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 1.8%, and AbbVie Inc (Symbol: ABBV) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ... |
23,253 | 2022-07-19 00:00:00 UTC | J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance | ABBV | https://www.nasdaq.com/articles/jj-jnj-beats-on-q2-earnings-sales-lowers-2022-guidance | null | null | Johnson & Johnson’s JNJ second-quarter 2022 earnings came in at $2.59 per share, which beat the Zacks Consensus Estimate of $2.57. Earnings increased 4.4% from the year-ago period.
Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported second-quarter earnings... | Johnson & Johnson Price, Consensus and EPS Surprise Johnson & Johnson price-consensus-eps-surprise-chart | Johnson & Johnson Quote Some better-ranked stocks from the same space include Merck MRK, Bayer BAYRY and AbbVie ABBV. While Bayer sports a Zacks Rank of 1, Merck and AbbVie have a Zacks Rank of 2 (Buy). AbbVie sto... | Johnson & Johnson Price, Consensus and EPS Surprise Johnson & Johnson price-consensus-eps-surprise-chart | Johnson & Johnson Quote Some better-ranked stocks from the same space include Merck MRK, Bayer BAYRY and AbbVie ABBV. While Bayer sports a Zacks Rank of 1, Merck and AbbVie have a Zacks Rank of 2 (Buy). AbbVie sto... | Johnson & Johnson Price, Consensus and EPS Surprise Johnson & Johnson price-consensus-eps-surprise-chart | Johnson & Johnson Quote Some better-ranked stocks from the same space include Merck MRK, Bayer BAYRY and AbbVie ABBV. While Bayer sports a Zacks Rank of 1, Merck and AbbVie have a Zacks Rank of 2 (Buy). AbbVie sto... | Johnson & Johnson Price, Consensus and EPS Surprise Johnson & Johnson price-consensus-eps-surprise-chart | Johnson & Johnson Quote Some better-ranked stocks from the same space include Merck MRK, Bayer BAYRY and AbbVie ABBV. While Bayer sports a Zacks Rank of 1, Merck and AbbVie have a Zacks Rank of 2 (Buy). AbbVie sto... |
23,254 | 2022-07-18 00:00:00 UTC | $192 Price Target Makes AbbVie Stock a Notable Healthcare Pick | ABBV | https://www.nasdaq.com/articles/%24192-price-target-makes-abbvie-stock-a-notable-healthcare-pick | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Illinois-headquartered pharmaceutical firm AbbVie (NYSE:ABBV) never ceases to innovate in the healthcare market. A big-bank analyst just raised his price target on ABBV stock and AbbVie’s diversified product portfolio enhances the company’s value to both pa... | A big-bank analyst just raised his price target on ABBV stock and AbbVie’s diversified product portfolio enhances the company’s value to both patients and shareholders. Morgan Stanley analyst Terence Flynn acknowledged that AbbVie could face competition now that the company has lost exclusivity in the U.S. with rheumat... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Illinois-headquartered pharmaceutical firm AbbVie (NYSE:ABBV) never ceases to innovate in the healthcare market. A big-bank analyst just raised his price target on ABBV stock and AbbVie’s diversified product portfolio enhances the company’s value to both pa... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Illinois-headquartered pharmaceutical firm AbbVie (NYSE:ABBV) never ceases to innovate in the healthcare market. A big-bank analyst just raised his price target on ABBV stock and AbbVie’s diversified product portfolio enhances the company’s value to both pa... | Ticker Company Price ABBV AbbVie Inc. $150.54 What’s Happening With ABBV Stock? ABBV stock has been in a holding pattern lately. The company pays a healthy dividend and ABBV stock is trading at a very reasonable valuation. |
23,255 | 2022-07-18 00:00:00 UTC | AbbVie (ABBV) Seeks EU Nod for Atogepant to Prevent Migraine | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-seeks-eu-nod-for-atogepant-to-prevent-migraine | null | null | AbbVie, Inc. ABBV announced that it has submitted a marketing authorization application (“MAA”) to the European Medicines Agency (EMA), seeking approval for its CGRP receptor antagonist, atogepant, for prophylaxis treatment of migraine.
The MAA seeks approval for atogepant in adult patients who have at least four migra... | AbbVie, Inc. ABBV announced that it has submitted a marketing authorization application (“MAA”) to the European Medicines Agency (EMA), seeking approval for its CGRP receptor antagonist, atogepant, for prophylaxis treatment of migraine. The grant of approval to atogepant will also make AbbVie the only company to offer ... | AbbVie, Inc. ABBV announced that it has submitted a marketing authorization application (“MAA”) to the European Medicines Agency (EMA), seeking approval for its CGRP receptor antagonist, atogepant, for prophylaxis treatment of migraine. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Another Stock ... | AbbVie, Inc. ABBV announced that it has submitted a marketing authorization application (“MAA”) to the European Medicines Agency (EMA), seeking approval for its CGRP receptor antagonist, atogepant, for prophylaxis treatment of migraine. AbbVie Inc. Price AbbVie Inc. price | AbbVie Inc. Quote Zacks Rank & Another Stock ... | Last month, AbbVie filed a supplemental new drug application, seeking approval for Qulipta, as a preventive treatment for chronic migraine. AbbVie, Inc. ABBV announced that it has submitted a marketing authorization application (“MAA”) to the European Medicines Agency (EMA), seeking approval for its CGRP receptor antag... |
23,256 | 2022-07-18 00:00:00 UTC | AbbVie: EMA's CHMP To Review Marketing Authorization Application For Migraine Drug Atogepant | ABBV | https://www.nasdaq.com/articles/abbvie%3A-emas-chmp-to-review-marketing-authorization-application-for-migraine-drug | null | null | (RTTNews) - AbbVie (ABBV) announced it has submitted a marketing authorization application or MAA to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.
The Committee for Medicinal Products for Human Use or CHMP will review the at... | (RTTNews) - AbbVie (ABBV) announced it has submitted a marketing authorization application or MAA to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month. And, AbbVie would become the only company with a portfolio of medicines to of... | (RTTNews) - AbbVie (ABBV) announced it has submitted a marketing authorization application or MAA to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month. And, AbbVie would become the only company with a portfolio of medicines to of... | (RTTNews) - AbbVie (ABBV) announced it has submitted a marketing authorization application or MAA to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month. And, AbbVie would become the only company with a portfolio of medicines to of... | (RTTNews) - AbbVie (ABBV) announced it has submitted a marketing authorization application or MAA to the European Medicines Agency for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month. And, AbbVie would become the only company with a portfolio of medicines to of... |
23,257 | 2022-07-17 00:00:00 UTC | Best Stocks for 2022: After Two Quarters, Who Holds The Lead? | ABBV | https://www.nasdaq.com/articles/best-stocks-for-2022%3A-after-two-quarters-who-holds-the-lead | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
At the end of each year, InvestorPlace invites its analysts and writers to take a stab at picking one stock they think will do better than the rest during the next year. Nine analysts chose stocks this year, and our readers chose their favorite in an open p... | ABBV Abbvie $153.62 ARHS Arhaus $4.95 DRRSF Arianne Phosphate $0.32 BMY Bristol-Myers Squibb $75.65 EPR EPR Properties $49.21 KLIC Kulicke and Soffa $45.43 NVDA Nvidia $157.62 POSAF POSaBit Systems $0.51 ROKU Roku $85.77 SAH Sonic Automotive $36.58 Best Stocks for 2022: AbbVie (ABBV) AbbVie (NYSE:ABBV), chosen by Bob C... | ABBV Abbvie $153.62 ARHS Arhaus $4.95 DRRSF Arianne Phosphate $0.32 BMY Bristol-Myers Squibb $75.65 EPR EPR Properties $49.21 KLIC Kulicke and Soffa $45.43 NVDA Nvidia $157.62 POSAF POSaBit Systems $0.51 ROKU Roku $85.77 SAH Sonic Automotive $36.58 Best Stocks for 2022: AbbVie (ABBV) AbbVie (NYSE:ABBV), chosen by Bob C... | ABBV Abbvie $153.62 ARHS Arhaus $4.95 DRRSF Arianne Phosphate $0.32 BMY Bristol-Myers Squibb $75.65 EPR EPR Properties $49.21 KLIC Kulicke and Soffa $45.43 NVDA Nvidia $157.62 POSAF POSaBit Systems $0.51 ROKU Roku $85.77 SAH Sonic Automotive $36.58 Best Stocks for 2022: AbbVie (ABBV) AbbVie (NYSE:ABBV), chosen by Bob C... | ABBV Abbvie $153.62 ARHS Arhaus $4.95 DRRSF Arianne Phosphate $0.32 BMY Bristol-Myers Squibb $75.65 EPR EPR Properties $49.21 KLIC Kulicke and Soffa $45.43 NVDA Nvidia $157.62 POSAF POSaBit Systems $0.51 ROKU Roku $85.77 SAH Sonic Automotive $36.58 Best Stocks for 2022: AbbVie (ABBV) AbbVie (NYSE:ABBV), chosen by Bob C... |
23,258 | 2022-07-17 00:00:00 UTC | Is InMode a Good Stock to Buy Now? | ABBV | https://www.nasdaq.com/articles/is-inmode-a-good-stock-to-buy-now | null | null | In 2021, it seemed as if medical technology stocks could do no wrong. Shares of cosmetic sculpting device manufacturer InMode (NASDAQ: INMD) more than doubled as enthusiasm for all things new and medically related reached a fever pitch.
Shares of InMode have tanked 72% since they hit an all-time high last November. Hig... | Botox from AbbVie (NYSE: ABBV) isn't the same as treatment with one of InMode's devices, but it's a good indicator for the overall minimally invasive cosmetic alteration space. Shares of cosmetic sculpting device manufacturer InMode (NASDAQ: INMD) more than doubled as enthusiasm for all things new and medically related... | Botox from AbbVie (NYSE: ABBV) isn't the same as treatment with one of InMode's devices, but it's a good indicator for the overall minimally invasive cosmetic alteration space. Shares of cosmetic sculpting device manufacturer InMode (NASDAQ: INMD) more than doubled as enthusiasm for all things new and medically related... | Botox from AbbVie (NYSE: ABBV) isn't the same as treatment with one of InMode's devices, but it's a good indicator for the overall minimally invasive cosmetic alteration space. Reasons to buy InMode now InMode markets minimally invasive cosmetic sculpting devices that employ a proprietary radio-frequency (RF) technolog... | Botox from AbbVie (NYSE: ABBV) isn't the same as treatment with one of InMode's devices, but it's a good indicator for the overall minimally invasive cosmetic alteration space. Reasons to buy InMode now InMode markets minimally invasive cosmetic sculpting devices that employ a proprietary radio-frequency (RF) technolog... |
23,259 | 2022-07-17 00:00:00 UTC | 3 Dividend Growth Stocks to Buy in July | ABBV | https://www.nasdaq.com/articles/3-dividend-growth-stocks-to-buy-in-july | null | null | What's better than stocks with a strong dividend? That's an easy question. The answer: Stocks with a strong dividend and share price that have excellent prospects to grow.
We asked three Motley Fool contributors to identify dividend growth stocks that are great picks to buy in July. Here's why they chose Abbott Laborat... | Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). Keeping it in the family Keith Speights (AbbVie): I agree with David's optimism about Abbott. AbbVie was part of Abbott until 2013. | Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). Keeping it in the family Keith Speights (AbbVie): I agree with David's optimism about Abbott. AbbVie was part of Abbott until 2013. | Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). Keeping it in the family Keith Speights (AbbVie): I agree with David's optimism about Abbott. AbbVie was part of Abbott until 2013. | I think that AbbVie will be able to continue increasing its dividend for a long time to come. Here's why they chose Abbott Laboratories (NYSE: ABT), AbbVie (NYSE: ABBV), and Johnson & Johnson (NYSE: JNJ). Keeping it in the family Keith Speights (AbbVie): I agree with David's optimism about Abbott. |
23,260 | 2022-07-16 00:00:00 UTC | Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever | ABBV | https://www.nasdaq.com/articles/want-to-get-richer-5-best-stocks-to-buy-now-and-hold-forever-0 | null | null | Healthcare is a massive industry; worldwide healthcare spending exceeded $8 trillion yearly in 2020 and 2021. Such an essential and lucrative field is fertile ground for great stocks.
You don't need to swing for a home run; hitting consistent base hits can get the job done. In other words, building wealth can be as eas... | A pharmaceutical leader AbbVie (NYSE: ABBV) was spun off from the fourth stock on this list in 2013 and has become one of the world's largest pharmaceutical companies. ABBV Revenue (TTM) data by YCharts. Humira's protection expires next year, but AbbVie's made acquisitions and developed its pipeline to drive long-term ... | A pharmaceutical leader AbbVie (NYSE: ABBV) was spun off from the fourth stock on this list in 2013 and has become one of the world's largest pharmaceutical companies. ABBV Revenue (TTM) data by YCharts. Humira's protection expires next year, but AbbVie's made acquisitions and developed its pipeline to drive long-term ... | A pharmaceutical leader AbbVie (NYSE: ABBV) was spun off from the fourth stock on this list in 2013 and has become one of the world's largest pharmaceutical companies. ABBV Revenue (TTM) data by YCharts. Humira's protection expires next year, but AbbVie's made acquisitions and developed its pipeline to drive long-term ... | A pharmaceutical leader AbbVie (NYSE: ABBV) was spun off from the fourth stock on this list in 2013 and has become one of the world's largest pharmaceutical companies. ABBV Revenue (TTM) data by YCharts. Humira's protection expires next year, but AbbVie's made acquisitions and developed its pipeline to drive long-term ... |
23,261 | 2022-07-15 00:00:00 UTC | This Stock Is Down By 13% This Year: Here's Why It's a Buy | ABBV | https://www.nasdaq.com/articles/this-stock-is-down-by-13-this-year%3A-heres-why-its-a-buy | null | null | It's been a mixed year for pharma giant Pfizer (NYSE: PFE). While the company's coronavirus-related portfolio continues to hit it out of the park, its shares have dropped by 13% since the beginning of the year. True, that's better than the performance of the S&P 500, but Pfizer is severely lagging similarly sized pharm... | True, that's better than the performance of the S&P 500, but Pfizer is severely lagging similarly sized pharma giants, including AbbVie, Eli Lilly, and Johnson & Johnson, among others. Even a fraction of their current sales would allow Pfizer to continue growing its revenue at a good clip compared to its pre-pandemic y... | True, that's better than the performance of the S&P 500, but Pfizer is severely lagging similarly sized pharma giants, including AbbVie, Eli Lilly, and Johnson & Johnson, among others. With a low cash payout ratio of 27.7%, Pfizer isn't done rewarding shareholders with dividend increases, something it is accustomed to ... | True, that's better than the performance of the S&P 500, but Pfizer is severely lagging similarly sized pharma giants, including AbbVie, Eli Lilly, and Johnson & Johnson, among others. Since it is difficult to predict how demand for COVID-19 vaccines and therapies will shape up after this year, the rest of Pfizer's lin... | True, that's better than the performance of the S&P 500, but Pfizer is severely lagging similarly sized pharma giants, including AbbVie, Eli Lilly, and Johnson & Johnson, among others. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market. * They just revealed what... |
23,262 | 2022-07-15 00:00:00 UTC | Zacks Investment Ideas feature highlights: Dollar Tree, AbbVie and Sysco | ABBV | https://www.nasdaq.com/articles/zacks-investment-ideas-feature-highlights%3A-dollar-tree-abbvie-and-sysco | null | null | For Immediate Release
Chicago, IL – July 15, 2022 – Today, Zacks Investment Ideas feature highlights Dollar Tree, Inc. DLTR, AbbVie ABBV and Sysco Corp. SYY.
3 Recession-Proof Stocks Up 10% in 2022 to Buy Right Now
Inflation showed no signs of cooling in June, with prices up 9.1% from a year ago to top estimates. Costs... | For Immediate Release Chicago, IL – July 15, 2022 – Today, Zacks Investment Ideas feature highlights Dollar Tree, Inc. DLTR, AbbVie ABBV and Sysco Corp. SYY. AbbVie Discount retail is a somewhat recession-proof space, as is the wider healthcare field, for obvious reasons. AbbVie is a pharmaceutical giant that's more di... | For Immediate Release Chicago, IL – July 15, 2022 – Today, Zacks Investment Ideas feature highlights Dollar Tree, Inc. DLTR, AbbVie ABBV and Sysco Corp. SYY. The firm's Large Cap Pharmaceuticals industry sits in the top 33% of 250 Zacks industries and ABBV lands an overall "A" VGM grade. AbbVie Discount retail is a som... | For Immediate Release Chicago, IL – July 15, 2022 – Today, Zacks Investment Ideas feature highlights Dollar Tree, Inc. DLTR, AbbVie ABBV and Sysco Corp. SYY. AbbVie Discount retail is a somewhat recession-proof space, as is the wider healthcare field, for obvious reasons. AbbVie is a pharmaceutical giant that's more di... | AbbVie Inc. (ABBV): Free Stock Analysis Report For Immediate Release Chicago, IL – July 15, 2022 – Today, Zacks Investment Ideas feature highlights Dollar Tree, Inc. DLTR, AbbVie ABBV and Sysco Corp. SYY. AbbVie Discount retail is a somewhat recession-proof space, as is the wider healthcare field, for obvious reasons. |
23,263 | 2022-07-14 00:00:00 UTC | 3 Recession-Proof Stocks Up 10% in 2022 to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-recession-proof-stocks-up-10-in-2022-to-buy-right-now | null | null | Inflation showed no signs of cooling in June, with prices up 9.1% from a year ago to top estimates. Costs were up nearly across the board and are essentially washing away Americans’ wage gains. U.S. consumers are already feeling historically beaten down as they watch gas prices and grocery bills surge, and their sentim... | AbbVie ABBV Discount retail is a somewhat recession-proof space, as is the wider healthcare field, for obvious reasons. AbbVie is a pharmaceutical giant that’s more diversified than ever and far less exposed to Humira’s growth, through its $63 billion purchase of Allergan in 2020. AbbVie now owns Botox and other popula... | AbbVie ABBV Discount retail is a somewhat recession-proof space, as is the wider healthcare field, for obvious reasons. AbbVie is a pharmaceutical giant that’s more diversified than ever and far less exposed to Humira’s growth, through its $63 billion purchase of Allergan in 2020. AbbVie now owns Botox and other popula... | AbbVie ABBV Discount retail is a somewhat recession-proof space, as is the wider healthcare field, for obvious reasons. AbbVie is a pharmaceutical giant that’s more diversified than ever and far less exposed to Humira’s growth, through its $63 billion purchase of Allergan in 2020. AbbVie now owns Botox and other popula... | The firm’s Large Cap Pharmaceuticals industry sits in the top 33% of 250 Zacks industries and ABBV lands an overall “A” VGM grade. AbbVie Inc. (ABBV): Free Stock Analysis Report AbbVie ABBV Discount retail is a somewhat recession-proof space, as is the wider healthcare field, for obvious reasons. |
23,264 | 2022-07-14 00:00:00 UTC | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | ABBV | https://www.nasdaq.com/articles/should-first-trust-morningstar-dividend-leaders-etf-fdl-be-on-your-investing-radar-1 | null | null | Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the First Trust Morningstar Dividend Leaders ETF (FDL) is a passively managed exchange traded fund launched on 03/09/2006.
The fund is sponsored by First Trust Advisors. It has amassed assets over $2.90 billion, making it one of ... | Looking at individual holdings, At&t Inc. (T) accounts for about 9.26% of total assets, followed by Abbvie Inc. (ABBV) and Chevron Corporation (CVX). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the First Trust Morningstar Divi... | Looking at individual holdings, At&t Inc. (T) accounts for about 9.26% of total assets, followed by Abbvie Inc. (ABBV) and Chevron Corporation (CVX). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the First Trust Morningstar Divi... | Looking at individual holdings, At&t Inc. (T) accounts for about 9.26% of total assets, followed by Abbvie Inc. (ABBV) and Chevron Corporation (CVX). AbbVie Inc. (ABBV): Free Stock Analysis Report Alternatives First Trust Morningstar Dividend Leaders ETF holds a Zacks ETF Rank of 2 (Buy), which is based on expected ass... | Looking at individual holdings, At&t Inc. (T) accounts for about 9.26% of total assets, followed by Abbvie Inc. (ABBV) and Chevron Corporation (CVX). AbbVie Inc. (ABBV): Free Stock Analysis Report Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the First Trust Morningstar Divi... |
23,265 | 2022-07-14 00:00:00 UTC | 3 Inflation-Resistant Stocks You Can Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-inflation-resistant-stocks-you-can-buy-right-now | null | null | The last time inflation was this high, the IBM personal computer was less than one year old, and Dallas and The Jeffersons ranked among the most watched TV shows.
While the stock market was down back in early 1982, there were still some businesses that handled inflation pretty well. The same is true today. Here are thr... | Although this will make a dent in the company's revenue and earnings temporarily, AbbVie should rebound quickly thanks to its strong product lineup and pipeline programs. AbbVie AbbVie (NYSE: ABBV) already ranks as one of the largest drugmakers in the world. AbbVie is able to pass higher costs along to payers relativel... | See the 10 stocks *Stock Advisor returns as of June 2, 2022 Keith Speights has positions in AbbVie, Berkshire Hathaway (B shares), Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. AbbVie AbbVie (NYSE: ABBV) already ranks as one of the largest drugmakers in the world. AbbVie is able to pass ... | See the 10 stocks *Stock Advisor returns as of June 2, 2022 Keith Speights has positions in AbbVie, Berkshire Hathaway (B shares), Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. AbbVie AbbVie (NYSE: ABBV) already ranks as one of the largest drugmakers in the world. AbbVie is able to pass ... | While the overall stock market has floundered so far this year, AbbVie's shares have soared. AbbVie AbbVie (NYSE: ABBV) already ranks as one of the largest drugmakers in the world. AbbVie is able to pass higher costs along to payers relatively easily. |
23,266 | 2022-07-14 00:00:00 UTC | 2 Top Biotech Stocks Defying the Bear Market | ABBV | https://www.nasdaq.com/articles/2-top-biotech-stocks-defying-the-bear-market | null | null | Uncertainty over elevated inflation, future interest rate hikes, and a potential recession has weighed heavily on financial markets in 2022. In fact, the S&P 500 index has dipped 19% year to date.
But some sectors have fared far better to this point -- even as the markets have plunged. Since prescription drugs are need... | AbbVie (NYSE: ABBV) and Bristol-Myers Squibb (NYSE: BMY) are two of the biggest and best pharma companies in the world that income investors should consider buying. AbbVie Chicago-based AbbVie owns the top-selling drug in the world, called Humira. That's because AbbVie has nearly 60 compounds in its pipeline across the... | Bristol-Myers Squibb Like AbbVie, Bristol-Myers Squibb also has top-selling drugs facing patent expiration this decade. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Kody Kester has positions in AbbVie, Bristol Myers Squibb, and Pfizer. AbbVie (NYSE: ABBV) and Bristol-Myers Squibb (NYSE: BMY) are two of t... | AbbVie's forward price-to-earnings (P/E) ratio stands at about 11, which isn't a steep valuation for a stock that is a member of the Dividend Kings. Bristol-Myers Squibb Like AbbVie, Bristol-Myers Squibb also has top-selling drugs facing patent expiration this decade. See the 10 stocks *Stock Advisor returns as of June... | Bristol-Myers Squibb Like AbbVie, Bristol-Myers Squibb also has top-selling drugs facing patent expiration this decade. * They just revealed what they believe are the ten best stocks for investors to buy right now... and AbbVie wasn't one of them! AbbVie (NYSE: ABBV) and Bristol-Myers Squibb (NYSE: BMY) are two of the ... |
23,267 | 2022-07-14 00:00:00 UTC | Here's How You Can Earn 10% of Your Investment Back in Dividends | ABBV | https://www.nasdaq.com/articles/heres-how-you-can-earn-10-of-your-investment-back-in-dividends | null | null | Do you want to collect 10% of your investment back in dividends? There are stocks that yield that much right now, but there's often a significant risk with seeking out those types of investments. Generally, stocks with such high yields either have unsustainable payout ratios or their shares have been crashing heavily, ... | And with the drugmaker's top-selling drug, Humira, facing patent expiration next year, AbbVie definitely has plenty of incentive to work on strengthening its business however it can before that happens. A dividend growth stock that could make earning 10% back in dividends a reality is healthcare company and top drugmak... | A dividend growth stock that could make earning 10% back in dividends a reality is healthcare company and top drugmaker AbbVie (NYSE: ABBV). But over the years, AbbVie has been increasing its payouts. And with the drugmaker's top-selling drug, Humira, facing patent expiration next year, AbbVie definitely has plenty of ... | A dividend growth stock that could make earning 10% back in dividends a reality is healthcare company and top drugmaker AbbVie (NYSE: ABBV). But over the years, AbbVie has been increasing its payouts. And with the drugmaker's top-selling drug, Humira, facing patent expiration next year, AbbVie definitely has plenty of ... | But over the years, AbbVie has been increasing its payouts. A dividend growth stock that could make earning 10% back in dividends a reality is healthcare company and top drugmaker AbbVie (NYSE: ABBV). And with the drugmaker's top-selling drug, Humira, facing patent expiration next year, AbbVie definitely has plenty of ... |
23,268 | 2022-07-13 00:00:00 UTC | Noteworthy Wednesday Option Activity: ABBV, C, QCOM | ABBV | https://www.nasdaq.com/articles/noteworthy-wednesday-option-activity%3A-abbv-c-qcom | null | null | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 32,846 contracts has been traded thus far today, a contract volume which is representative of approximately 3.3 million underlying shares (given that every ... | Especially high volume was seen for the $140 strike call option expiring July 15, 2022, with 4,515 contracts trading so far today, representing approximately 451,500 underlying shares of ABBV. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Sy... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 32,846 contracts has been traded thus far today, a contract volume which is representative of approximately 3.3 million underlying shares (given that every ... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 32,846 contracts has been traded thus far today, a contract volume which is representative of approximately 3.3 million underlying shares (given that every ... | Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 32,846 contracts has been traded thus far today, a contract volume which is representative of approximately 3.3 million underlying shares (given that every ... |
23,269 | 2022-07-13 00:00:00 UTC | See Which Of The Latest 13F Filers Holds AbbVie | ABBV | https://www.nasdaq.com/articles/see-which-of-the-latest-13f-filers-holds-abbvie-1 | null | null | At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 06/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 13 of these funds. When hedge fund managers appear to be thinking alike, we find it is a good idea to take a closer look.
Before we proceed... | At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 06/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 13 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the ... | At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 06/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 13 of these funds. Existing -214 -$277 Resonant Capital Advisors LLC Existing +429 -$41 One Plus One Wealth Management LLC Existing -200 -$... | Existing -214 -$277 Resonant Capital Advisors LLC Existing +429 -$41 One Plus One Wealth Management LLC Existing -200 -$70 Diversified Trust Co Existing +7,044 +$758 RGT Wealth Advisors LLC Existing -126 -$40 First Affirmative Financial Network Existing +110 -$3 Red Door Wealth Management LLC Existing +403 +$1 RVW Weal... | At Holdings Channel, we have reviewed the latest batch of the 20 most recent 13F filings for the 06/30/2022 reporting period, and noticed that AbbVie Inc (Symbol: ABBV) was held by 13 of these funds. Existing -214 -$277 Resonant Capital Advisors LLC Existing +429 -$41 One Plus One Wealth Management LLC Existing -200 -$... |
23,270 | 2022-07-13 00:00:00 UTC | Better Dividend Stock: AbbVie or Johnson & Johnson? | ABBV | https://www.nasdaq.com/articles/better-dividend-stock%3A-abbvie-or-johnson-johnson | null | null | The pharmaceutical industry is chock-full of companies that offer attractive dividends. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) especially stand out. They're two of the largest drugmakers in the world with a long lineup of successful products.
But which is the better dividend stock? Here's how AbbVie and ... | The main knock against AbbVie is that it faces the U.S. loss of exclusivity (LOE) for Humira next year. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) especially stand out. Here's how AbbVie and Johnson & Johnson stack up against each other. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) especially stand out. Here's how AbbVie and Johnson & Johnson stack up against each other. The case for AbbVie Probably the first thing most investors look at with a dividend stock is the yield. | The case for AbbVie Probably the first thing most investors look at with a dividend stock is the yield. Like AbbVie, Johnson & Johnson is a Dividend King. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) especially stand out. | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) especially stand out. Here's how AbbVie and Johnson & Johnson stack up against each other. The case for AbbVie Probably the first thing most investors look at with a dividend stock is the yield. |
23,271 | 2022-07-12 00:00:00 UTC | Ex-Dividend Reminder: Cracker Barrel Old Country Store, DTE Energy and AbbVie | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder%3A-cracker-barrel-old-country-store-dte-energy-and-abbvie | null | null | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/22, Cracker Barrel Old Country Store Inc (Symbol: CBRL), DTE Energy Co (Symbol: DTP), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Cracker Barrel Old Country Store Inc will pay its quarterly divi... | If they do continue, the current estimated yields on annualized basis would be 5.85% for Cracker Barrel Old Country Store Inc, 6.08% for DTE Energy Co, and 3.66% for AbbVie Inc. Free Report: Top 7%+ Dividends (paid monthly) In Tuesday trading, Cracker Barrel Old Country Store Inc shares are currently up about 0.6%, DTE... | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/22, Cracker Barrel Old Country Store Inc (Symbol: CBRL), DTE Energy Co (Symbol: DTP), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Cracker Barrel Old Country Store Inc will pay its quarterly divi... | Looking at the universe of stocks we cover at Dividend Channel, on 7/14/22, Cracker Barrel Old Country Store Inc (Symbol: CBRL), DTE Energy Co (Symbol: DTP), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. Cracker Barrel Old Country Store Inc will pay its quarterly divi... | Cracker Barrel Old Country Store Inc (Symbol: CBRL): DTE Energy Co (Symbol: DTP): AbbVie Inc (Symbol: ABBV): In general, dividends are not always predictable, following the ups and downs of company profits over time. If they do continue, the current estimated yields on annualized basis would be 5.85% for Cracker Barrel... |
23,272 | 2022-07-12 00:00:00 UTC | San Francisco reaches $54 million opioid settlement with Teva and Allergan | ABBV | https://www.nasdaq.com/articles/san-francisco-reaches-%2454-million-opioid-settlement-with-teva-and-allergan-0 | null | null | By Dietrich Knauth
July 12 (Reuters) - Teva Pharmaceutical Industries Inc TEVA.TA and AbbVie's ABBV.N Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced.
Under the dea... | By Dietrich Knauth July 12 (Reuters) - Teva Pharmaceutical Industries Inc TEVA.TA and AbbVie's ABBV.N Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced. San Francisco... | By Dietrich Knauth July 12 (Reuters) - Teva Pharmaceutical Industries Inc TEVA.TA and AbbVie's ABBV.N Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced. Teva's settle... | By Dietrich Knauth July 12 (Reuters) - Teva Pharmaceutical Industries Inc TEVA.TA and AbbVie's ABBV.N Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced. Teva's settle... | By Dietrich Knauth July 12 (Reuters) - Teva Pharmaceutical Industries Inc TEVA.TA and AbbVie's ABBV.N Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced. Teva's settle... |
23,273 | 2022-07-12 00:00:00 UTC | What's Happening With Merck Stock? | ABBV | https://www.nasdaq.com/articles/whats-happening-with-merck-stock | null | null | Merck stock (NYSE: MRK) has seen a 21% rise YTD, significantly outperforming its peers and the broader markets, with Johnson & Johnson stock up 4%, Pfizer stock down 6%, AbbVie stock up 12%, and the S&P500 index down 19%. There are a couple of factors aiding Merck’s stock growth. Firstly, the company’s Q1 performance w... | Merck stock (NYSE: MRK) has seen a 21% rise YTD, significantly outperforming its peers and the broader markets, with Johnson & Johnson stock up 4%, Pfizer stock down 6%, AbbVie stock up 12%, and the S&P500 index down 19%. This acquisition, if successful, subject to regulatory approvals, will likely be looked at as a po... | Merck stock (NYSE: MRK) has seen a 21% rise YTD, significantly outperforming its peers and the broader markets, with Johnson & Johnson stock up 4%, Pfizer stock down 6%, AbbVie stock up 12%, and the S&P500 index down 19%. At its current levels, MRK stock is trading at 13x forward adjusted earnings, in line with the las... | Merck stock (NYSE: MRK) has seen a 21% rise YTD, significantly outperforming its peers and the broader markets, with Johnson & Johnson stock up 4%, Pfizer stock down 6%, AbbVie stock up 12%, and the S&P500 index down 19%. Furthermore, we find MRK stock to have only a little room for growth and estimate Merck’s valuatio... | Merck stock (NYSE: MRK) has seen a 21% rise YTD, significantly outperforming its peers and the broader markets, with Johnson & Johnson stock up 4%, Pfizer stock down 6%, AbbVie stock up 12%, and the S&P500 index down 19%. However, Merck is more in the limelight for its possible acquisition of Seagen Inc. in a deal valu... |
23,274 | 2022-07-12 00:00:00 UTC | San Francisco reaches $54 million opioid settlement with Teva and Allergan | ABBV | https://www.nasdaq.com/articles/san-francisco-reaches-%2454-million-opioid-settlement-with-teva-and-allergan | null | null | July 12 (Reuters) - Teva Pharmaceutical Industries Inc TEVA.TA and AbbVie's ABBV.N Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced.
(Reporting by Brendan Pierson in... | July 12 (Reuters) - Teva Pharmaceutical Industries Inc TEVA.TA and AbbVie's ABBV.N Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced. (Reporting by Brendan Pierson in... | July 12 (Reuters) - Teva Pharmaceutical Industries Inc TEVA.TA and AbbVie's ABBV.N Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced. (Reporting by Brendan Pierson in... | July 12 (Reuters) - Teva Pharmaceutical Industries Inc TEVA.TA and AbbVie's ABBV.N Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced. (Reporting by Brendan Pierson in... | July 12 (Reuters) - Teva Pharmaceutical Industries Inc TEVA.TA and AbbVie's ABBV.N Allergan business unit reached a $58 million opioid settlement with the city of San Francisco over claims that they fueled an opioid epidemic in the city, San Francisco City Attorney David Chiu announced. (Reporting by Brendan Pierson in... |
23,275 | 2022-07-11 00:00:00 UTC | Notable ETF Inflow Detected - IVW, LLY, TMO, ABBV | ABBV | https://www.nasdaq.com/articles/notable-etf-inflow-detected-ivw-lly-tmo-abbv | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $158.5 million dollar inflow -- that's a 0.5% increase week over week in outstanding units (from 463,550,000 to... | Among the largest underlying components of IVW, in trading today Eli Lilly (Symbol: LLY) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.3%, and AbbVie Inc (Symbol: ABBV) is up by about 0.5%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year pri... | Among the largest underlying components of IVW, in trading today Eli Lilly (Symbol: LLY) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.3%, and AbbVie Inc (Symbol: ABBV) is up by about 0.5%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year pri... | Among the largest underlying components of IVW, in trading today Eli Lilly (Symbol: LLY) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.3%, and AbbVie Inc (Symbol: ABBV) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... | Among the largest underlying components of IVW, in trading today Eli Lilly (Symbol: LLY) is trading flat, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.3%, and AbbVie Inc (Symbol: ABBV) is up by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF ... |
23,276 | 2022-07-11 00:00:00 UTC | Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? | ABBV | https://www.nasdaq.com/articles/is-trending-stock-abbvie-inc.-abbv-a-buy-now-0 | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Over the past month, shares of this drugmaker have returned +6.7%, compared to the Zacks S&P 500 composite's -5.1% change. Dur... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industr... | For the next fiscal year, the consensus earnings estimate of $11.86 indicates a change of -15.3% from what AbbVie is expected to report a year ago. Last Reported Results and Surprise History AbbVie reported revenues of $13.54 billion in the last reported quarter, representing a year-over-year change of +4.1%. AbbVie (A... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which ... | The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #4 (Sell) for AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. During this period, the Zacks Large Cap Pharmaceuticals industry, which ... |
23,277 | 2022-07-10 00:00:00 UTC | What's Driving AbbVie Stock Higher? | ABBV | https://www.nasdaq.com/articles/whats-driving-abbvie-stock-higher | null | null | AbbVie stock (NYSE: ABBV) has seen a 14% rise YTD, marking a significant outperformance compared to some of its peers and the broader markets, with Johnson & Johnson stock rising 4%, Pfizer stock down 9%, and the S&P 500 index falling 20. Looking at the longer term, ABBV stock is up a solid 74% from levels seen in late... | AbbVie stock (NYSE: ABBV) has seen a 14% rise YTD, marking a significant outperformance compared to some of its peers and the broader markets, with Johnson & Johnson stock rising 4%, Pfizer stock down 9%, and the S&P 500 index falling 20. Looking at the longer term, ABBV stock is up a solid 74% from levels seen in late... | AbbVie stock (NYSE: ABBV) has seen a 14% rise YTD, marking a significant outperformance compared to some of its peers and the broader markets, with Johnson & Johnson stock rising 4%, Pfizer stock down 9%, and the S&P 500 index falling 20. Total [2] ABBV Return 1% 14% 146% S&P 500 Return 1% -20% 71% Trefis Multi-Strateg... | AbbVie stock (NYSE: ABBV) has seen a 14% rise YTD, marking a significant outperformance compared to some of its peers and the broader markets, with Johnson & Johnson stock rising 4%, Pfizer stock down 9%, and the S&P 500 index falling 20. AbbVie’s revenue, which grew 71% to $57 billion over the last twelve months, comp... | AbbVie stock (NYSE: ABBV) has seen a 14% rise YTD, marking a significant outperformance compared to some of its peers and the broader markets, with Johnson & Johnson stock rising 4%, Pfizer stock down 9%, and the S&P 500 index falling 20. Total [2] ABBV Return 1% 14% 146% S&P 500 Return 1% -20% 71% Trefis Multi-Strateg... |
23,278 | 2022-07-10 00:00:00 UTC | How to Earn $10,000 a Year in Passive Retirement Income | ABBV | https://www.nasdaq.com/articles/how-to-earn-%2410000-a-year-in-passive-retirement-income | null | null | Most people would probably agree that it's pretty sweet to see cash trickle into your account every quarter, especially if you didn't need to sell your labor to make it happen. As it turns out, generating passive income in retirement is a lot easier than it sounds, assuming you invest in the right high-quality dividend... | In this vein, shares of a major healthcare stock like AbbVie (NYSE: ABBV) are quite attractive for passive-income investors because such companies tend to have a history of consistently distributing dividends and of hiking their payouts repeatedly over long periods. Furthermore, investors can bet on AbbVie continuing t... | Aside from AbbVie, Gilead Sciences (NASDAQ: GILD) and GSK (NYSE: GSK) are two other drug developers which feature similar business models and dividend yields, though their dividend hikes aren't as favorable, so their future payouts probably won't be as lucrative. In this vein, shares of a major healthcare stock like Ab... | Aside from AbbVie, Gilead Sciences (NASDAQ: GILD) and GSK (NYSE: GSK) are two other drug developers which feature similar business models and dividend yields, though their dividend hikes aren't as favorable, so their future payouts probably won't be as lucrative. If we assume that dividend hikes enable the yield to rem... | If we assume that dividend hikes enable the yield to remain in roughly the same range as it's in right now over the next 25 years, you'd only need to invest a more manageable sum of around $9,800 per year into AbbVie or (preferably) a basket of stocks with similar yields to get to the same dividend income after that. I... |
23,279 | 2022-07-10 00:00:00 UTC | 3 Unstoppable Dividend Stocks to Buy and Never Sell | ABBV | https://www.nasdaq.com/articles/3-unstoppable-dividend-stocks-to-buy-and-never-sell | null | null | Unfortunately, "set and forget" isn't a strategy you can use with many stocks. Too many things can change over the years that can make a once-attractive stock an albatross on your portfolio.
There are exceptions, though. Some of them even offer solid dividends that boost your total returns significantly over time. Here... | Even though the company will inevitably face patent expirations for key products in the future, its commitment to research and business development should make AbbVie a winner for a long time to come. AbbVie Several of the same arguments for Johnson & Johnson also apply to AbbVie (NYSE: ABBV). Like J&J, AbbVie is a Div... | See the 10 stocks *Stock Advisor returns as of June 2, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. AbbVie Several of the same arguments for Johnson & Johnson also apply to AbbVie (NYSE: ABBV). Like J&J, AbbVie is a Dividend King -- albeit ju... | See the 10 stocks *Stock Advisor returns as of June 2, 2022 Keith Speights has positions in AbbVie, Brookfield Renewable Corporation Inc., and Brookfield Renewable Partners L.P. AbbVie Several of the same arguments for Johnson & Johnson also apply to AbbVie (NYSE: ABBV). Like J&J, AbbVie is a Dividend King -- albeit ju... | AbbVie Several of the same arguments for Johnson & Johnson also apply to AbbVie (NYSE: ABBV). Like J&J, AbbVie is a Dividend King -- albeit just barely, with a 50-year streak of dividend increases. AbbVie has trounced the overall market so far in 2022. |
23,280 | 2022-07-10 00:00:00 UTC | 2 Surefire Dividend Stocks I'd Buy Now and Hold for at Least a Decade | ABBV | https://www.nasdaq.com/articles/2-surefire-dividend-stocks-id-buy-now-and-hold-for-at-least-a-decade | null | null | It's hard to watch the value of your portfolio decline in a bear market. The pain is so acute right now that dividend-paying stocks tied to businesses with reliable cash flows have a hard time finding buyers at sensible prices.
Times like these are when the world's most successful investors do the most shopping. The ma... | AbbVie AbbVie (NYSE: ABBV) offers a healthy dividend yield of 3.7% right now, slightly less than Digital Realty Trust -- but probably not for very long. This is a great stock to buy now because the investments AbbVie has made with Humira could allow it to continue raising its dividend at a hair-raising pace for another... | AbbVie AbbVie (NYSE: ABBV) offers a healthy dividend yield of 3.7% right now, slightly less than Digital Realty Trust -- but probably not for very long. This is a great stock to buy now because the investments AbbVie has made with Humira could allow it to continue raising its dividend at a hair-raising pace for another... | AbbVie AbbVie (NYSE: ABBV) offers a healthy dividend yield of 3.7% right now, slightly less than Digital Realty Trust -- but probably not for very long. This is a great stock to buy now because the investments AbbVie has made with Humira could allow it to continue raising its dividend at a hair-raising pace for another... | AbbVie AbbVie (NYSE: ABBV) offers a healthy dividend yield of 3.7% right now, slightly less than Digital Realty Trust -- but probably not for very long. This is a great stock to buy now because the investments AbbVie has made with Humira could allow it to continue raising its dividend at a hair-raising pace for another... |
23,281 | 2022-07-09 00:00:00 UTC | This Company Could Ease the Pain in a Bear Market | ABBV | https://www.nasdaq.com/articles/this-company-could-ease-the-pain-in-a-bear-market | null | null | Biotechnology company Vertex Pharmaceuticals (NASDAQ: VRTX) carved a name for itself in cystic fibrosis but has been slow to diversify into other diseases. That finally looks about to change as the company is on the verge of entering several new markets and dramatically expanding its total addressable patient populatio... | Potential competitor AbbVie gifted Vertex several more years of market dominance when it decided to scrap its phase 2 trial of a combination drug because it did not meet pre-determined criteria at the interim analysis. The company is looking to expand the label to treat younger children, and developing a new mRNA treat... | Potential competitor AbbVie gifted Vertex several more years of market dominance when it decided to scrap its phase 2 trial of a combination drug because it did not meet pre-determined criteria at the interim analysis. The company does face competition in blood disorders from Bluebird Bio's gene therapy program, with t... | Potential competitor AbbVie gifted Vertex several more years of market dominance when it decided to scrap its phase 2 trial of a combination drug because it did not meet pre-determined criteria at the interim analysis. Vertex sets high bar in cystic fibrosis Vertex is the undisputed leader in the cystic fibrosis field,... | Potential competitor AbbVie gifted Vertex several more years of market dominance when it decided to scrap its phase 2 trial of a combination drug because it did not meet pre-determined criteria at the interim analysis. Vertex sets high bar in cystic fibrosis Vertex is the undisputed leader in the cystic fibrosis field,... |
23,282 | 2022-07-08 00:00:00 UTC | Chinook (KDNY) Stock Rallies 24.2% in 3 Months: Here's Why | ABBV | https://www.nasdaq.com/articles/chinook-kdny-stock-rallies-24.2-in-3-months%3A-heres-why | null | null | Shares of Chinook Therapeutics KDNY have risen 24.2% in the past three months against the industry’s 5% decline.
Image Source: Zacks Investment Research
Berkley, CA-based Chinook is focused on developing precision medicines, targeting kidney diseases. With no marketable drugs in its portfolio, the company is entirely ... | Atrasentan was originally developed by AbbVie ABBV. The candidate was in-licensed by Chinook in December 2019 as part of a license agreement with ABBV. Per the terms of agreement, AbbVie is eligible to receive milestone payments of $135 million in aggregate. | Atrasentan was originally developed by AbbVie ABBV. The candidate was in-licensed by Chinook in December 2019 as part of a license agreement with ABBV. Per the terms of agreement, AbbVie is eligible to receive milestone payments of $135 million in aggregate. | Atrasentan was originally developed by AbbVie ABBV. The candidate was in-licensed by Chinook in December 2019 as part of a license agreement with ABBV. Per the terms of agreement, AbbVie is eligible to receive milestone payments of $135 million in aggregate. | Atrasentan was originally developed by AbbVie ABBV. The candidate was in-licensed by Chinook in December 2019 as part of a license agreement with ABBV. Per the terms of agreement, AbbVie is eligible to receive milestone payments of $135 million in aggregate. |
23,283 | 2022-07-08 00:00:00 UTC | Want to Beat the Bear Market? Try These 2 Stocks | ABBV | https://www.nasdaq.com/articles/want-to-beat-the-bear-market-try-these-2-stocks | null | null | The bear market has sent plenty of great companies into the doldrums. Most of us know that just by looking at our portfolios. And that's OK. We're in this for the long term. Once economic pressures ease, our favorite companies have a great chance of rebounding -- and gaining over time.
Meanwhile, it's always a good ide... | Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) are both gaining so far this year -- even as the S&P 500 declines. AbbVie AbbVie is on its way to dominating the prescription drug market. This is even as AbbVie's biggest blockbuster -- Humira -- prepares to face biosimilar competition in the U.S. next year... | This is even as AbbVie's biggest blockbuster -- Humira -- prepares to face biosimilar competition in the U.S. next year. Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) are both gaining so far this year -- even as the S&P 500 declines. AbbVie AbbVie is on its way to dominating the prescription drug market... | Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) are both gaining so far this year -- even as the S&P 500 declines. AbbVie AbbVie is on its way to dominating the prescription drug market. This is even as AbbVie's biggest blockbuster -- Humira -- prepares to face biosimilar competition in the U.S. next year... | This is even as AbbVie's biggest blockbuster -- Humira -- prepares to face biosimilar competition in the U.S. next year. But AbbVie has plenty of other products to keep revenue and profit growing over the long term. Vertex Pharmaceuticals (NASDAQ: VRTX) and AbbVie (NYSE: ABBV) are both gaining so far this year -- even ... |
23,284 | 2022-07-07 00:00:00 UTC | Health Care Sector Update for 07/07/2022: CTMX,ABBV,SRNE,KALV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-07-07-2022%3A-ctmxabbvsrnekalv | null | null | Health care stocks still were narrowly higher this afternoon, with the NYSE Health Care Index rising 0.2% and the SPDR Health Care Select Sector ETF (XLV) up 0.3%.
The Nasdaq Biotechnology index was climbing 1.9% in recent trade.
In company news, CytomX Therapeutics (CTMX) dropped nearly 40% to a record low of $1.19 af... | AbbVie (ABBV) slid 0.5% on Thursday after overnight paring its FY22 profit forecast by $0.14 per share on both sides of its prior outlook to a new range of $13.78 to $13.98 per share, excluding one-time items, to account for a $269 million pre-tax expense for acquired in-process research and development and milestone p... | AbbVie (ABBV) slid 0.5% on Thursday after overnight paring its FY22 profit forecast by $0.14 per share on both sides of its prior outlook to a new range of $13.78 to $13.98 per share, excluding one-time items, to account for a $269 million pre-tax expense for acquired in-process research and development and milestone p... | AbbVie (ABBV) slid 0.5% on Thursday after overnight paring its FY22 profit forecast by $0.14 per share on both sides of its prior outlook to a new range of $13.78 to $13.98 per share, excluding one-time items, to account for a $269 million pre-tax expense for acquired in-process research and development and milestone p... | AbbVie (ABBV) slid 0.5% on Thursday after overnight paring its FY22 profit forecast by $0.14 per share on both sides of its prior outlook to a new range of $13.78 to $13.98 per share, excluding one-time items, to account for a $269 million pre-tax expense for acquired in-process research and development and milestone p... |
23,285 | 2022-07-07 00:00:00 UTC | Senate Finance report says AbbVie shifted profit overseas to cut taxes | ABBV | https://www.nasdaq.com/articles/senate-finance-report-says-abbvie-shifted-profit-overseas-to-cut-taxes | null | null | By Michael Erman
July 7 (Reuters) - Drugmaker AbbVie Inc ABBV.O generates most of its sales in the United States, while shifting most of its profits overseas in order to avoid U.S. taxes, an interim report from the Senate Finance Committee said on Thursday.
According to the Democratic staff report, more than 75% of Ill... | By Michael Erman July 7 (Reuters) - Drugmaker AbbVie Inc ABBV.O generates most of its sales in the United States, while shifting most of its profits overseas in order to avoid U.S. taxes, an interim report from the Senate Finance Committee said on Thursday. In 2018, Reuters laid out how AbbVie reported its income in lo... | By Michael Erman July 7 (Reuters) - Drugmaker AbbVie Inc ABBV.O generates most of its sales in the United States, while shifting most of its profits overseas in order to avoid U.S. taxes, an interim report from the Senate Finance Committee said on Thursday. In 2018, Reuters laid out how AbbVie reported its income in lo... | By Michael Erman July 7 (Reuters) - Drugmaker AbbVie Inc ABBV.O generates most of its sales in the United States, while shifting most of its profits overseas in order to avoid U.S. taxes, an interim report from the Senate Finance Committee said on Thursday. According to the Democratic staff report, more than 75% of Ill... | By Michael Erman July 7 (Reuters) - Drugmaker AbbVie Inc ABBV.O generates most of its sales in the United States, while shifting most of its profits overseas in order to avoid U.S. taxes, an interim report from the Senate Finance Committee said on Thursday. According to the Democratic staff report, more than 75% of Ill... |
23,286 | 2022-07-07 00:00:00 UTC | Health Care Sector Update for 07/07/2022: KALV, SRNE, ABBV | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-for-07-07-2022%3A-kalv-srne-abbv | null | null | Health care stocks were narrowly higher this afternoon, with the NYSE Health Care Index rising 0.2% and the SPDR Health Care Select Sector ETF (XLV) up 0.1%.
The Nasdaq Biotechnology index, however, was climbing 2.4% in recent trade.
In company news, KalVista Pharmaceuticals (KALV) rose over 12% after the early-stage d... | AbbVie (ABBV) slid 0.4% on Thursday after overnight paring its FY22 profit forecast by $0.14 per share on both sides of its prior outlook to a new range of $13.78 to $13.98 per share, excluding one-time items, to account for a $269 million pre-tax expense for acquired in-process research and development and milestone p... | AbbVie (ABBV) slid 0.4% on Thursday after overnight paring its FY22 profit forecast by $0.14 per share on both sides of its prior outlook to a new range of $13.78 to $13.98 per share, excluding one-time items, to account for a $269 million pre-tax expense for acquired in-process research and development and milestone p... | AbbVie (ABBV) slid 0.4% on Thursday after overnight paring its FY22 profit forecast by $0.14 per share on both sides of its prior outlook to a new range of $13.78 to $13.98 per share, excluding one-time items, to account for a $269 million pre-tax expense for acquired in-process research and development and milestone p... | AbbVie (ABBV) slid 0.4% on Thursday after overnight paring its FY22 profit forecast by $0.14 per share on both sides of its prior outlook to a new range of $13.78 to $13.98 per share, excluding one-time items, to account for a $269 million pre-tax expense for acquired in-process research and development and milestone p... |
23,287 | 2022-07-07 00:00:00 UTC | Best Stocks for 2022: AbbVie Is a Recession-Resistant Dividend King | ABBV | https://www.nasdaq.com/articles/best-stocks-for-2022%3A-abbvie-is-a-recession-resistant-dividend-king | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Editor’s note: This column is part of InvestorPlace.com’s Best Stocks for 2022 contest. Bob Ciura’s pick for the contest is AbbVie (NYSE:ABBV) stock.
The stock market recently entered bear market territory. Although the S&P 500 index has regained some groun... | AbbVie continues to generate strong growth even in a difficult economic backdrop due to its high-quality product portfolio. Bob Ciura’s pick for the contest is AbbVie (NYSE:ABBV) stock. This is why I continue to recommend investors consider pharmaceutical giant AbbVie (NYSE:ABBV). | ABBV AbbVie $153.15 ABBV Stock First Quarter Earnings In the first quarter of 2022, AbbVie generated revenue of $13.5 billion, representing 4% year-over-year growth. AbbVie’s global aesthetics portfolio generated revenue growth of 22.5% for the first quarter, and global Botox cosmetic revenue increased 36.6%. Bob Ciura... | AbbVie stock also has a high dividend yield, with regular dividend increases — AbbVie is one of just 65 Dividend Aristocrats, and one of just 44 Dividend Kings. ABBV AbbVie $153.15 ABBV Stock First Quarter Earnings In the first quarter of 2022, AbbVie generated revenue of $13.5 billion, representing 4% year-over-year g... | Indeed, AbbVie expects its annual revenue to decline next year as a result. ABBV stock has a secure dividend payout. Bob Ciura’s pick for the contest is AbbVie (NYSE:ABBV) stock. |
23,288 | 2022-07-06 00:00:00 UTC | These 5 Top Stocks Are Set to Outperform in a Recession | ABBV | https://www.nasdaq.com/articles/these-5-top-stocks-are-set-to-outperform-in-a-recession | null | null | The Federal Reserve is grappling with elevated inflation by taking a hawkish stance and raising interest rates. The threat of a recession is real, and many consider it inevitable. This is the bad news. The good news is that some stocks perform well no matter what, others perform better historically during economic diff... | ABBV data by YCharts American Tower is one of the world's largest real estate investment trusts (REITs) with 221,000 communication sites globally. There are several tried-and-true methods to take advantage of this market drop: Look for companies with recession-proof income that pay significant dividends, like prescript... | There are several tried-and-true methods to take advantage of this market drop: Look for companies with recession-proof income that pay significant dividends, like prescription drugmaker AbbVie (NYSE: ABBV) and cell tower REIT American Tower (NYSE: AMT) Find a company that benefits from sky-high inflation and has a his... | There are several tried-and-true methods to take advantage of this market drop: Look for companies with recession-proof income that pay significant dividends, like prescription drugmaker AbbVie (NYSE: ABBV) and cell tower REIT American Tower (NYSE: AMT) Find a company that benefits from sky-high inflation and has a his... | There are several tried-and-true methods to take advantage of this market drop: Look for companies with recession-proof income that pay significant dividends, like prescription drugmaker AbbVie (NYSE: ABBV) and cell tower REIT American Tower (NYSE: AMT) Find a company that benefits from sky-high inflation and has a his... |
23,289 | 2022-07-05 00:00:00 UTC | AbbVie (ABBV) Gains But Lags Market: What You Should Know | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-gains-but-lags-market%3A-what-you-should-know-3 | null | null | In the latest trading session, AbbVie (ABBV) closed at $153.93, marking a +0.08% move from the previous day. The stock lagged the S&P 500's daily gain of 0.16%. At the same time, the Dow lost 0.42%, and the tech-heavy Nasdaq gained 0.49%.
Coming into today, shares of the drugmaker had gained 4.96% in the past month. In... | In the latest trading session, AbbVie (ABBV) closed at $153.93, marking a +0.08% move from the previous day. AbbVie will be looking to display strength as it nears its next earnings release. In that report, analysts expect AbbVie to post earnings of $3.43 per share. | In the latest trading session, AbbVie (ABBV) closed at $153.93, marking a +0.08% move from the previous day. ABBV's full-year Zacks Consensus Estimates are calling for earnings of $14.02 per share and revenue of $59.63 billion. AbbVie will be looking to display strength as it nears its next earnings release. | ABBV's full-year Zacks Consensus Estimates are calling for earnings of $14.02 per share and revenue of $59.63 billion. In the latest trading session, AbbVie (ABBV) closed at $153.93, marking a +0.08% move from the previous day. AbbVie will be looking to display strength as it nears its next earnings release. | In that report, analysts expect AbbVie to post earnings of $3.43 per share. In the latest trading session, AbbVie (ABBV) closed at $153.93, marking a +0.08% move from the previous day. AbbVie will be looking to display strength as it nears its next earnings release. |
23,290 | 2022-07-05 00:00:00 UTC | Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now? | ABBV | https://www.nasdaq.com/articles/is-first-trust-health-care-alphadex-etf-fxh-a-strong-etf-right-now-2 | null | null | Making its debut on 05/08/2007, smart beta exchange traded fund First Trust Health Care AlphaDEX ETF (FXH) provides investors broad exposure to the Health Care ETFs category of the market.
What Are Smart Beta ETFs?
The ETF industry has traditionally been dominated by products based on market capitalization weighted ind... | Taking into account individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of the fund's total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report There are some investors, though, who think it's possibl... | Taking into account individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of the fund's total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report Vanguard Health Care ETF (VHT) tracks MSCI US Investable... | Taking into account individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of the fund's total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report Making its debut on 05/08/2007, smart beta exchange trad... | Taking into account individual holdings, Abbvie Inc. (ABBV) accounts for about 2.47% of the fund's total assets, followed by Universal Health Services, Inc. (class B) (UHS) and Regeneron Pharmaceuticals, Inc. (REGN). AbbVie Inc. (ABBV): Free Stock Analysis Report Making its debut on 05/08/2007, smart beta exchange trad... |
23,291 | 2022-07-05 00:00:00 UTC | This Blockbuster Drug from AbbVie Is Closer to Another Major Indication | ABBV | https://www.nasdaq.com/articles/this-blockbuster-drug-from-abbvie-is-closer-to-another-major-indication | null | null | The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. This would be to treat patients with moderate-to-severe ulcerative colitis who had... | The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. But what could that mean for the pharma stock AbbVie's sales? So, how much could a... | The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. But what could that mean for the pharma stock AbbVie's sales? So, how much could a... | The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. But what could that mean for the pharma stock AbbVie's sales? So, how much could a... | The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. But what could that mean for the pharma stock AbbVie's sales? So, how much could a... |
23,292 | 2022-07-03 00:00:00 UTC | 2 First-Rate ETFs for Stock Dividends | ABBV | https://www.nasdaq.com/articles/2-first-rate-etfs-for-stock-dividends | null | null | Exchange-traded funds (ETFs) designed to generate dividend income have become more popular in this market cycle as investors seek investments that can balance out the losses in their portfolios. Dividend-focused ETFs can provide income if you decide to take the distributions, but they can also boost the total return of... | Currently, the three largest holdings in the portfolio are AbbVie (2.3%), GlaxoSmithKline (2.2%), and AT&T (2.2%). Exchange-traded funds (ETFs) designed to generate dividend income have become more popular in this market cycle as investors seek investments that can balance out the losses in their portfolios. These two ... | Currently, the three largest holdings in the portfolio are AbbVie (2.3%), GlaxoSmithKline (2.2%), and AT&T (2.2%). iShares Core High Dividend ETF The iShares Core High Dividend ETF (NYSEMKT: HDV) tracks an index comprising high-yield dividend stocks -- the Morningstar Dividend Yield Focus Index. Pacer Global Cash Cows ... | Currently, the three largest holdings in the portfolio are AbbVie (2.3%), GlaxoSmithKline (2.2%), and AT&T (2.2%). iShares Core High Dividend ETF The iShares Core High Dividend ETF (NYSEMKT: HDV) tracks an index comprising high-yield dividend stocks -- the Morningstar Dividend Yield Focus Index. Pacer Global Cash Cows ... | Currently, the three largest holdings in the portfolio are AbbVie (2.3%), GlaxoSmithKline (2.2%), and AT&T (2.2%). iShares Core High Dividend ETF The iShares Core High Dividend ETF (NYSEMKT: HDV) tracks an index comprising high-yield dividend stocks -- the Morningstar Dividend Yield Focus Index. And June was a rough mo... |
23,293 | 2022-07-02 00:00:00 UTC | 3 Stocks You Can Buy and Hold for Decades | ABBV | https://www.nasdaq.com/articles/3-stocks-you-can-buy-and-hold-for-decades | null | null | Three little words can make you a lot of money over the long term: Buy and hold. However, the catch is that you must find the right stocks for those three words to work most effectively.
We asked three Motley Fool contributors which stocks you can buy and hold for decades. Here's why they picked AbbVie (NYSE: ABBV), Br... | Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Vertex Pharmaceuticals (NASDAQ: VRTX). Defying the market downturn Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie is currently defying gravity. Even better, AbbVie has outperformed the broader market in the past three, five, and 10 y... | Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Vertex Pharmaceuticals (NASDAQ: VRTX). AbbVie boasts multiple blockbuster products, including its blockbuster immunology medicine Humira. Defying the market downturn Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie is currently defying... | I agree with Prosper and David that AbbVie and Bristol Myers Squibb are great stocks to buy and hold for decades. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Vertex Pharmaceuticals (NASDAQ: VRTX). Defying the market downturn Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie is cu... | Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Vertex Pharmaceuticals (NASDAQ: VRTX). Defying the market downturn Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie is currently defying gravity. Even better, AbbVie has outperformed the broader market in the past three, five, and 10 y... |
23,294 | 2022-07-01 00:00:00 UTC | Amgen's Beating the Market -- Here's Why It's a Buy Now | ABBV | https://www.nasdaq.com/articles/amgens-beating-the-market-heres-why-its-a-buy-now | null | null | Amgen (NASDAQ: AMGN) is the world's largest biotechnology company by revenue, focusing on using living cells to create a robust product portfolio of biologic medicines to treat serious diseases in several areas -- among them, cardiovascular, oncology, and neuroscience. In 2022, the company's stock has returned over 9% ... | But come Jan. 31, the doors will open to Amgen, which should help the company grab a portion of the $20 billion in peak annual sales that AbbVie has enjoyed from Humira. One of the top drugs up for patent expiration in 2023 is AbbVie's Humira. Under a settlement reached in 2017 between AbbVie and Amgen, Amgen has had t... | One of the top drugs up for patent expiration in 2023 is AbbVie's Humira. Under a settlement reached in 2017 between AbbVie and Amgen, Amgen has had to sit on its already FDA-approved potential biosimilar blockbuster, Amjevita, for the U.S. market. But come Jan. 31, the doors will open to Amgen, which should help the c... | One of the top drugs up for patent expiration in 2023 is AbbVie's Humira. Under a settlement reached in 2017 between AbbVie and Amgen, Amgen has had to sit on its already FDA-approved potential biosimilar blockbuster, Amjevita, for the U.S. market. But come Jan. 31, the doors will open to Amgen, which should help the c... | One of the top drugs up for patent expiration in 2023 is AbbVie's Humira. Under a settlement reached in 2017 between AbbVie and Amgen, Amgen has had to sit on its already FDA-approved potential biosimilar blockbuster, Amjevita, for the U.S. market. But come Jan. 31, the doors will open to Amgen, which should help the c... |
23,295 | 2022-07-01 00:00:00 UTC | The 3 Best Dividend Aristocrat Stocks in the First Half of 2022: Are They Buys Now? | ABBV | https://www.nasdaq.com/articles/the-3-best-dividend-aristocrat-stocks-in-the-first-half-of-2022%3A-are-they-buys-now | null | null | Dividend stocks aren't always known for generating sizzling gains. However, investors have flocked to some dividend payers this year as the overall market has tumbled.
Some of the biggest winners are among the elite group of S&P 500 members that have increased their dividends for at least 25 consecutive years. Here are... | Probably the biggest reason for AbbVie's market-beating performance this year, though, is that the company has chalked up several regulatory wins for its drugs in recent months. AbbVie Two sectors have performed the best so far this year: energy and healthcare. The third-place spot belongs to a healthcare stock: AbbVie... | AbbVie Two sectors have performed the best so far this year: energy and healthcare. The third-place spot belongs to a healthcare stock: AbbVie (NYSE: ABBV). AbbVie's strong dividend yield of nearly 3.7% has no doubt attracted some investors. | 10 stocks we like better than AbbVie When our award-winning analyst team has a stock tip, it can pay to listen. See the 10 stocks *Stock Advisor returns as of June 2, 2022 Keith Speights has positions in AbbVie. AbbVie Two sectors have performed the best so far this year: energy and healthcare. | AbbVie Two sectors have performed the best so far this year: energy and healthcare. The third-place spot belongs to a healthcare stock: AbbVie (NYSE: ABBV). AbbVie's strong dividend yield of nearly 3.7% has no doubt attracted some investors. |
23,296 | 2022-06-30 00:00:00 UTC | SPLG, BRK.B, ABBV, BAC: ETF Inflow Alert | ABBV | https://www.nasdaq.com/articles/splg-brk.b-abbv-bac%3A-etf-inflow-alert | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 ETF (Symbol: SPLG) where we have detected an approximate $205.8 million dollar inflow -- that's a 1.6% increase week over week in outstanding units (from 281,900,000 t... | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is down about 0.9%, AbbVie Inc (Symbol: ABBV) is off about 1%, and Bank of America Corp (Symbol: BAC) is lower by about 3.1%. For a complete list of holdings, visit the SPLG Holdings page » The chart below shows... | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is down about 0.9%, AbbVie Inc (Symbol: ABBV) is off about 1%, and Bank of America Corp (Symbol: BAC) is lower by about 3.1%. For a complete list of holdings, visit the SPLG Holdings page » The chart below shows... | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is down about 0.9%, AbbVie Inc (Symbol: ABBV) is off about 1%, and Bank of America Corp (Symbol: BAC) is lower by about 3.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs... | Among the largest underlying components of SPLG, in trading today Berkshire Hathaway Inc New (Symbol: BRK.B) is down about 0.9%, AbbVie Inc (Symbol: ABBV) is off about 1%, and Bank of America Corp (Symbol: BAC) is lower by about 3.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs... |
23,297 | 2022-06-30 00:00:00 UTC | 2 of the Safest Stocks to Buy in a Recession | ABBV | https://www.nasdaq.com/articles/2-of-the-safest-stocks-to-buy-in-a-recession | null | null | What's next for the U.S. economy? It's hard to even wager a guess. Soaring oil prices caused by Russia's invasion of Ukraine at the tail end of a global pandemic present an especially unpredictable economic environment.
In uncertain times like these, it helps to own stocks that you can rely on to produce strong cash fl... | With lots of high-margin revenue from top-selling drugs, there's a good chance that AbbVie stock will remain a safe haven even if the U.S. economy plunges into a deep recession. AbbVie Shares of AbbVie (NYSE: ABBV) are up by about 13% this year, which is a lot better than the benchmark S&P 500 index, which has lost 20%... | AbbVie Shares of AbbVie (NYSE: ABBV) are up by about 13% this year, which is a lot better than the benchmark S&P 500 index, which has lost 20% over the same period. With lots of high-margin revenue from top-selling drugs, there's a good chance that AbbVie stock will remain a safe haven even if the U.S. economy plunges ... | AbbVie Shares of AbbVie (NYSE: ABBV) are up by about 13% this year, which is a lot better than the benchmark S&P 500 index, which has lost 20% over the same period. With lots of high-margin revenue from top-selling drugs, there's a good chance that AbbVie stock will remain a safe haven even if the U.S. economy plunges ... | This isn't going to stop AbbVie from growing, though. AbbVie Shares of AbbVie (NYSE: ABBV) are up by about 13% this year, which is a lot better than the benchmark S&P 500 index, which has lost 20% over the same period. With lots of high-margin revenue from top-selling drugs, there's a good chance that AbbVie stock will... |
23,298 | 2022-06-29 00:00:00 UTC | The Best Stocks to Invest $5,000 in Right Now | ABBV | https://www.nasdaq.com/articles/the-best-stocks-to-invest-%245000-in-right-now-0 | null | null | It's nearly impossible to come up with a "best stock to invest in" list that everyone will agree on. That's partly because the stock market brings together people with different goals, investing styles, and income levels. However, beating the market is a pretty good goal.
Let's look at two stocks worth investing $5,000... | Let's look at two stocks worth investing $5,000 in right now for investors who want to score market-beating returns in the long run: AbbVie (NYSE: ABBV) and Intuitive Surgical (NASDAQ: ISRG). AbbVie is part of the exclusive group of Dividend Kings -- having raised its payouts for 50 years when including its time under ... | Let's look at two stocks worth investing $5,000 in right now for investors who want to score market-beating returns in the long run: AbbVie (NYSE: ABBV) and Intuitive Surgical (NASDAQ: ISRG). Intuitive Surgical Intuitive Surgical hasn't performed nearly as well as AbbVie this year. ABBV data by YCharts 1. | Let's look at two stocks worth investing $5,000 in right now for investors who want to score market-beating returns in the long run: AbbVie (NYSE: ABBV) and Intuitive Surgical (NASDAQ: ISRG). AbbVie Shares of AbbVie have easily outperformed the market this year, but the company remains reasonably valued. Intuitive Surg... | One more reason to consider investing in AbbVie's stock is the dividend. Intuitive Surgical Intuitive Surgical hasn't performed nearly as well as AbbVie this year. Let's look at two stocks worth investing $5,000 in right now for investors who want to score market-beating returns in the long run: AbbVie (NYSE: ABBV) and... |
23,299 | 2022-06-29 00:00:00 UTC | Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now? | ABBV | https://www.nasdaq.com/articles/is-most-watched-stock-abbvie-inc.-abbv-worth-betting-on-now-0 | null | null | AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
Shares of this drugmaker have returned +3.5% over the past month versus the Zacks S&P 500 composite's -8% change. The Zacks La... | Bottom Line The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about AbbVie. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie b... | Last Reported Results and Surprise History AbbVie reported revenues of $13.54 billion in the last reported quarter, representing a year-over-year change of +4.1%. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost... | Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, AbbVie is rated Zacks Rank #4 (Sell). AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has los... | For the next fiscal year, the consensus earnings estimate of $11.86 indicates a change of -15.4% from what AbbVie is expected to report a year ago. AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. The Zacks Large Cap Pharmaceuticals industry, to which AbbVie belongs, has lost 2.4% over this... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.